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 Introduction Inflammatory Bowel Disease (IBD) as a chronic disorder of the 
gastrointestinal tract depends on mutations in the NADPH oxidase complex, responsible for 
the production of reactive oxygen species (ROS).  IBD is refereed as Crohn's disease (CD) and 
ulcerative colitis (UC). Ncf1-mutation in mice leads to deficiency in ROS, rendering them 
susceptible to autoimmunity. As in humans, Ncf1-mutation leads to the lack of ROS in B10.Q 
mice. Studies focusing on how ROS-deficiency and colon-inflammation lead to tumorigenesis 
are still missing, as well as effective treatments. Hence the aim was to study how the lack of 
ROS influenced chronic DSS-induced colitis and the disease evolution to colon-adenocarcinoma 
in Ncf1-deficient mice and assess the effectiveness of caffeic acid-derivatives in human 
peripheral blood mononuclear cells (PBMCs) and human colon adenocarciona cell lines. 
 
 Methods Colitis was induced in Ncf1-mutant (Ncf1*) and wild-type (WT) B10.Q 
mice by oral administration of 3% (w/v) DSS. Two different colitis-induction protocols were 
used: Protocol 1- mice were submitted to 7 days DSS-induction, followed by 21 days of resting 
on normal water. Protocol 2- mice were submitted to 7 days of DSS-induction, followed by 14 
days of resting on normal water and a second 7 days DSS-cycle. Animals were monitored 
every 2 days for al terations of  col iti s-related cl inical  scores: weight loss, 
diarrhea, colorectal  bleeding and survival . Five Ncf1* and WT mice were sacrificed at 
the end of each time point: before the experiment had started and at days 22 and 30. Tissues 
were collected for histopathological analysis and assessment of colon lenght and spleen 
weight. The caffeic acid-based drugs were tested in human PBMCs and C2BBe1 and 
WiDr human colon-carcinoma cell  l ines  with 6h, 12h, 24h and 72h incubation 
periods. 
 
 Results  Colitis showed severer clinical and histological results in Ncf1* than in 
WT mice, with lower inflammatory reparation together with high grade dysplasia and invasive 
adenocarcinoma. Caffeic-acid derivatives markedly inhibited C2BBe1 and WIDr cell 
proliferation and high concentrations together with longer incubation periods enhanced 
proliferation of immune adaptive effector T cells.  
 
 Conclusion  We propose a new animal model as a novel tool to study chronic 
colitis-induced carcinogenesis, where the absence of ROS keeps iNOs overexpression in Ncf1* 
colon during the chronic process, which promotes the high grade dysplasia and 
adenocarcinoma formation. Caffeic-acid derivatives are presented as novel possible drug 
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candidates against carcinogenesis development, due their dual capacity to promote both 
cancer cell death and activation of the adaptive immune system cells. 
  
 Key-words IBD, colitis, immune response, dysplasia, colorectal cancer, caffeic acid-
derivatives. 
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Introdução A doença inflamatória do intestino (DII), referida como Doença de Crohn (DC) e 
Colite Ulcerativa (CU), leva modificações crónicas permanentes da estrutura gastrointestinal. 
Apesar das comuns características clinicas e patológicas, alguns fatores chave levam a que seja 
feita uma distinção das duas doenças. A DC pode envolver qualquer região do trato 
gastrointestinal, enquanto que CU afeta geralmente o reto, os perfis de resposta imune inata 
também contribuem a separação das doenças, sendo a DC caracterizada por um perfil Th1 e 
Th17, enquanto que a CU por um perfil Th2. A DII surge de uma resposta imune inflamatória 
inapropriada, em hospedeiros geneticamente susceptíveis e está ligada a mutações no 
complexo da NADPH oxidase, responsável pela produção de espécies reativas de oxigénio 
(ROS). Em murganho assim como nos humanos, a mutação no gene Ncf1 leva a uma 
deficiência na produção de ROS, tornando-os susceptíveis à autoimunidade. O 
desenvolvimento de cancro colo-retal é a complicação mais séria associada à cronicidade da 
DII. No entanto ainda estão em falta estudos que se foquem em como o défice de ROS e a 
inflamação do colon levam ao desenvolvimento tumoral, assim como tratamentos eficazes. 
Desta forma o objetivo  deste trabalho foi estudar como a falta de ROS influencia a colite 
crónica induzida por DSS e a evolução da doença em murganhos mutados no gene Ncf1. Além 
disso, propusemo-nos a testar a eficácia de compostos derivados do ácido caféico em células 
do sangue periférico humano e linhas humanas de adenocarcinoma do colon. 
 
Métodos A colite foi induzida em murganhos B10.Q mutados no gene Ncf1 (Ncf1*) e em 
WT, através de administração oral de DSS 3% (p/v). Foram aplicados dois protocolos 
diferentes: 1- os murganhos foram submetidos a 7 dias de indução com DSS, seguidos de 21 
dias de água normal; 2- os murganhos foram submetidos a 7 dias de indução com DSS, 
seguidos de 14 dias de água normal e um segundo ciclo de 7 dias de DSS. Os animais foram 
monitorizados de 2 em 2 dias para alterações clinicas relacionadas com a colite: perda de peso, 
diarreia, hemorragia colorretal e sobrevivência. Cinco murganhos Ncf1* e cinco controlos 
foram sacrificados, os colons foram removidos e corados com HE para análise histológica e 
avaliação do comprimento do colon e peso do baço, antes do início da experiência e nos dias 
22 e 30. Os compostos derivados de ácido caféico foram testados em células humanas do 
sangue periférico e linhas celulares humanas de adenocarcinoma (C2BBe1 e WIDr) com 
incubações de 6h, 12h, 24h e 72h. 
 
Resultados A colite mostrou ter resultados tanto clínicos como histológicos mais severos 
nos murganhos Ncf1* do que nos WT, apresentando para além de uma fraca reparação 
inflamatória o desenvolvimento de displasia de alto grau e adenocarcinoma invasivo. Os 
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derivados de ácido caféico inibiram marcadamente, com concentrações preferencialmente 
elevadas e ao fim de 72h de incubação a proliferação de células C2BBe1 e WIDr. 
Simultaneamente não se mostraram tóxicos para as células do sangue periférico e uma vez 
mais mostraram que elevadas concentrações e longos períodos de incubação favorecem a 
proliferação de células T efetoras do sistema imune adaptativo. 
 
 
Conclusão Propomos um novo modelo animal como ferramenta para estudar a 
carcinogénese induzida através da colite crónica, onde a ausência de ROS mantém a 
sobrexpressão de iNOS no colon de murganhos Ncf1* durante o processo crónico, levando ao 
desenvolvimento de displasia de alto grau e subsequentemente à formação de 
adenocarcinoma. Os derivados de ácido caféico são apresentados como uma nova possível 
droga no combate à carcinogénese, devido à sua dupla capacidade em promover a morte de 
células cancerígenas e a ativação de células do sistema imune adaptativo.  
 
 
Palavras-chave  DII, colite, resposta imune, displasia. cancro colorrectal, derivados de 
ácido caféico 
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Introduction 
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2. Introduction 
 
2.1 Inflammatory Bowel Disease 
 Inflammatory bowel disease (IBD) is a chronic relapsing idiopathic immunological 
disorder of the gastrointestinal tract, leading to long-term and occasionally permanent 
pathological modification of the gastro-intestinal structure [1, 2]. IBD encompasses as two 
major forms of bowel disease, Crohn's disease (CD) and ulcerative colitis (UC). Extensive 
evidence suggests that IBD arises from an inappropriate inflammatory immune response to 
intestinal microbes in a genetically susceptible host. Even though UC and CD have several 
common clinical and pathological characteristics, key features distinguish both diseases, 
suggesting that the main pathological courses in the two forms of the disease are distinctive 
[2-9]. 
 Crohn's disease can involve every part of the gastrointestinal tract, but normally, the 
terminal ileum, cecum, peri-anal area and colon are the most affected regions. CD is 
characterized by the presence of normal segments of the bowel between affected regions. 
Histologically is characterized by transmural inflammation that may involve any part of the 
gastrointestinal tract, dense infiltration of lymphocytes and macrophages, presence of 
granulomas in up to 60% of the patients and fissuring ulceration [3, 4, 6, 8-12]. 
 In Ulcerative Colitis, the inflammatory development involves the rectum and expands 
continuously until the proximal region. Histologically the inflammation involves superficial 
mucosal layers with infiltration of lymphocytes, granulocytes and loss of the goblet cells, 
presence of ulcerations and crypt abscesses can also occur [3, 4, 8, 11, 12].  
 
2.1.1 Epidemiology 
 There is a bimodal distribution of the disease in the population, most individuals (up to 
25% of the patients) [13] are diagnosed between ages 15 and 40 years, or in older individuals 
between 50-70 years old [3, 5, 14-17].  
 The colon is the frequent macroscopic site of disease in very young people, childhood-
onset of UC is usually extensive, whereas adults are equally probable to develop UC restricted 
to the distal colon. CD occurring earlier to puberty affects most males, whereas adult females 
are more commonly affected [13]. 
 The occurrence and prevalence of CD and UC varies around the world, but all races and 
ethnic groups are affected and the disease incidence is growing internationally [3, 16, 18]. In 
the absence of major genetic fluctuations by migration, alteration in the percentages in IBD 
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incidence within a country and the importance of the genetic factors, emphasize the 
magnitude of environmental factors in the pathogenesis.  
 It is known that ‘‘Westernization’’ of society is one of the reasons for recent increases 
in the incidence of IBD. Areas with the highest incidence and prevalence of IBD are Northern 
Europe and North America [3, 5, 13, 15, 19-22]. Besides westernization, there are other 
theories/hypothesis trying to explain the increase and the onset of the disease. The ‘‘cold 
chain hypothesis’’ proposes that refrigeration has gradually been changing the bacterial 
content of our diet, resulting in the increased growth of disease triggering organisms [13, 23]. 
‘‘Hygiene hypothesis’’ offers an alternative for the increase of IBD, asthma, rheumatoid 
arthritis, and type I diabetes in our society. The theory proposes that contact with pathogens 
and parasites during childhood, stimulates protective immunity that will prevent later 
aggressive immunologic processes, meaning that a cleaner environment/excessive sanitation 
could reduce the exposure to environmental antigens to the point of weakening the 
maturation of the mucosal immune system and induction of immune tolerance [2, 5, 13, 20, 
24, 25]. In spite of all the existing hypotheses to date, the most popular proposes that the 
onset or relapsing of IBD pathogenesis is due to the development of an extremely aggressive 
acquired immune response against a subset of commensal bacteria in a genetically susceptible 
host [2, 19]. 
 
2.1.2 Environmental triggers 
 Previous studies have implicated environmental factors as one of the causes in 
genetically predisposed hosts to IBD. The environmental triggers act in IBD by 
altering/disrupting the mucosal barrier integrity, changing immune responses, or the luminal 
microenvironment [2, 3]. 
  Antibiotics and diet (mostly diets with high contents of refined sugar and low on 
vegetable and fibre) can modify the luminal flora and dietary additives like aluminum and iron 
have an already well-defined role in stimulating bacterial virulence [26, 27].  
 Nonsteroidal anti-inflammatory drugs and acute infections can cause inflammation, 
which results in increased mucosal permeability, leading to increase uptake of commensal 
bacterial antigens, that stimulate the T-cell-mediated intestinal inflammation [2, 3, 28]. 
 Stress can alter mucosal permeability, mucosal blood flow, epithelial electrolyte, water 
secretion and expression of cytokines and neuropeptides. All referred factors seem to increase 
the likelihood of relapse in patients with inactive disease [2]. 
 Smoking, in CD, can cause changes in blood flow and mucus secretion weakening the 
mucosal barrier, exacerbating disease development and leading to fistulas and strictures 
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formation, increasing the need for medication and accelerating the need for surgery [22, 29, 
30]. Although smoking may anticipate a crises in CD's patients, it appears to be protective 
against UC [31]. In fact, nicotine patches are sometimes used for the treatment of UC. 
Experimental studies suggest that the beneficial effects of nicotine in UC are due to increased 
mucus production, decreased production of pro-inflammatory cytokines and nitric-oxide, and 
improvement of the intestinal barrier function, whereas nicotine’s negative effects in CD seem 
to be related to an increased influx of neutrophils into the intestinal mucosa [2, 3, 5, 15, 20]. 
 
2.1.3 Luminal antigens/gut flora 
 Studies in several different animal models have demonstrated that luminal flora is 
required for IBD to develop in a susceptible host. Genetically susceptible animals that are 
maintained in a germ-free environment since birth, only develop colitis when they acquire 
luminal flora, needed for the immune system activation [5, 6, 32]. Studies using only one 
species of bacteria, Bacteroids vulgatus, were able to induce colitis in IL-10-/- susceptible mice 
[33]. The normal mucosal microflora is required to initiate and/or maintain the inflammatory 
process, by providing one or more antigens or co-stimulatory factors that drive the immune 
response [3]. 
 Antigens of the microflora, are present in the body since the birth, so they might be 
subjected to an intra-thymic processing that allows the immune system to distinguish self-
antigens from non-self-antigens, so the hypothesis that the organism could be reacting to this 
antigens and mounting an autoimmune response, suggests that the chronic mucosal 
inflammation of IBD may be considered an autoimmune disease [2, 4]. 
 Although the gut microflora plays an important role in IBD, not all bacteria are 
potentially harmful, a class of organisms that are recently known as probiotics ameliorate 
inflammation as they are thought to work through the induction of suppressor cytokines  [34, 
35].  
 
2.1.4 The presence of abnormal microflora 
 Some studies suggest that IBD is associated with pathologic organisms that establish a 
type of low-grade infection in the mucosa inducing the inflammatory response, other propose 
that IBD patients have a defective epithelial barrier that enables the  proliferation of 
nonpathologic organisms, again promoting the inflammatory response [11]. 
 A previous study confirmed the presence of higher amounts of mucosa-associated 
bacteria in biopsies from IBD patients when compared with control subjects [36].  Darfeuille-
Michaud et al. also presented results on the increased mucosa-associated bacteria in IBD 
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subjects: 20-40% of CD's biopsy patients were associated with invasive E. coli against 6% of 
specimens from controls [37]. Fecal samples from CD patients show a reduced diversity when 
compared with healthy individuals. IBD patients exhibit a marked reduction in bacteria 
belonging to the Clostridium coccoides subgroup [38], and in particular Clostridium leptum 
[39]. High concentrations of fungal communities were repported in a study by Ott Kuhbacher 
et al. were they analyzed fecal biopsies from CD patients [40]. Studies using colonic mucosae 
cultures, revealed that CD disease patients have an increase content of bacteria compared to 
healthy individuals [41]. Another study by Favier , Neut et al. showed that bacterial enzyme 
activities, in particular b-D-galactosidase, were also decreased in fecal extracts from CD 
patients [42]. 
 Even though some authors discredit that IBD might be caused due a specific pathogen, 
some pathogenic and potential harmful enteric bacteria are seen more frequently in IBD 
patients than in healthy individuals: 
- Mycobacterium avium paratuberculosis (MAP), the causative agent of Johne's disease in 
cattle, which shares similarities to CD, characterized by granulomatous inflammation of the 
intestines [19, 43-46]. MAP can be cultured from blood of about 50% CD's patients and 22% of 
UC patients, but not controls [47].  Additional evidence demonstrated that T cells isolated from 
CD patients were very reactive to MAP, whereas this reactivity was absent in healthy control 
individuals [48]. Moreover, it has been shown that down-regulation of the autophagy gene, 
IRGM, alterations which are also connected to CD, leads to prolonged survival of MAP in 
macrophages [49]. 
- Helicobacter, cotton-top Tamarin colitis (CTT) is essentially the Helicobacter equivalent of 
MAP’s Johne’s disease but parallels with UC, with similar clinical and pathological findings [50]. 
A potential role for Helicobacter organisms is to orchestrate the change from a healthy 
microbiota to dysbiosis [43]. However, oftentimes the attempt to demonstrate their presence 
has failed. 
- Escherichia coli have been isolated in increased numbers from CD's patients and 
demonstrated to have greater adherent capacity to human cells, when compared with those 
isolated from controls, and had the ability to disrupt the intestinal barrier by producing α-
aemolysin [37]. These E. coli named adherent-invasive E. coli (AIEC) are able to invade 
intestinal epithelial cells and strain LF82 can invade human macrophages, survive and replicate 
for long periods [51]. Such infected macrophages release high levels of TNF-α, which is a key 
cytokine in intestinal inflammation and has been known to be released in large quantity in CD 
[35]. 
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 Complementary studies using molecular techniques to identify specific bacterial 
groups have also been applied to study bacterial microflora in IBD, however these studies do 
not support the presence of a specific, pathogenic organism in IBD [11]. 
 
2.2  Genetic 
 
2.2.1 Familial aggregation in IBD 
 Epidemiological and family studies have provided great evidence that genetic factors 
have an important role in determining susceptibility to IBD. First-degree relatives of patients 
with IBD have a 4-to-20-fold increased risk to develop the disease. People with CD have a first-
degree relative with the disease in 2% of the cases, and with IBD in 5% of the cases. Regarding 
people with UC, they usually have a first-degree relative with the disease in 5% of the cases, 
and with inflammatory bowel disease in 8% of the cases [15, 20, 52]. Despite the evidence 
supporting a genetic predisposition, most patients with IBD have no close relatives with IBD 
[3]. 
 
2.2.2 Disease aggregation in twins 
  The most compelling evidence of genetic influence in IBD comes from twin studies 
[53]. Monozygotic twins have a significantly concordance rate of 58% for CD, whereas only 
10% for UC. Comparing with dizygotic twins the concordance rate is not significantly different 
from that from all siblings. Therefore it appears that the genetic contribution to the 
development of IBD is more important in CD than in UC [3, 15, 54]. 
 
2.2.3 Susceptibility genes involved in IBD 
 Thus far, there have been two general approaches for gene identification in complex 
genetic disorders, like IBD, the use of genome-wide linkage studies and the testing of 
candidate genes. The tendency appears to be that the implicated genes in IBD regulate several 
biologic functions, including immunoregulation, mucosal barrier integrity and microbial 
clearance and/or homeostasis [2]. Nowadays several regions on chromosomes, 1, 3, 5, 6, 12, 
14, 16 and 19 have been renamed as IBD1–9 and in a few cases the gene or genes underlying 
the different chromosome loci that are linked to IBD were identified. However, the first and 
most promising candidate gene is associated with CD [20]. 
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 IBD-1: CARD15, also known as NOD2, (caspase recruitment domain family member 
15), is expressed in macrophages, dendritic cells, epithelial cells and paneth cells. [2, 4, 8, 55, 
56]. 
 There are three mutations/polymorphisms associated with NOD2/CARD15, causing 
amino-acid substitutions, Arg702Trp and Gly908Arg and a frameshift 1007fs—found in 
CARD15's region, which encodes a leucine-rich repeat (LRR) responsible for bacterial 
recognition. At least one of these mutations is present in 25–35% of CD patients of European 
ancestry [57]. The LRR region binds to muramyl dipeptide (MDP), which is the biologically 
active half of the peptidoglycan, a ever-present cell-wall polymer found in almost all bacteria 
[58, 59]. The binding of MDP to CARD15 activates nuclear factor NF-κB through a receptor-
interacting serine-theronine kinase-2 (RIPK2)- dependent signaling pathway, that forms part of 
a central signaling pathway that stimulates the transcription of multiple genes, that encode 
both pro-inflammatory and protective molecules [58, 60, 61]. The mutations Arg702Trp, 
Gly908Arg and 1007fs cause defective MDP binding [2, 9, 11, 55, 56, 62-64], and result in 
reduced macrophage activation by the NF-κB pathway and increased luminal bacterial 
populations [65]. This raised the question of how a mutation impairing NF-kB activation could 
lead to an increase in NF-kB-dependent inflammation. A study by Uehara, Yang et al. found 
two possible explanations. First, a host defense defect due to NOD2 impaired function allowed 
an increase in bacterial colonization of the gut wall leading afterwards to NF-kB stimulation by 
other mechanisms. Second, the ligand molecule for TLR2 can activate NF-kB independently of 
NOD2 [66]. NOD2 polymorphisms, when expressed within enterocytes and Paneth cells, are 
associated with lower production of anti-bacterial α-defensins [9]. This might lead to bacterial 
overgrowth and subsequent infection and chronic inflammation. Despite the presented facts, 
some studies suggest that NOD2 only plays a small role in the pathogenesis of the disease, 
because of its strongest association only with CD, also because the polymorphisms occur 
predominantly in patients with small bowel disease and are restricted to certain racial groups, 
which is indicative of the complexities of a multifactorial disorder [8, 55]. In patients with 
variant CARD15, homozygotes for this variant gene have a 20- to 40-fold increased risk of 
developing CD, whereas the heterozygotes have only 2- to 4-fold increased risk [8, 15]. 
Primary-monocyte-derived macrophages from patients with CD who are homozygous for the 
truncating mutation in the LRR sensor domain (Leu1007fsinsC)  have a globally blunted 
transcriptional response to MDP. Otherwise, NOD2 frameshift-mutation knock-in mice have an 
enhanced response to MDP and are susceptible to dextran sodium sulphate (DSS) colitis [9, 
67]. 
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 Regarding the linkage studies, no evidence was observed in CD-UC or UC- UC affected 
relative pairs, indicating that the susceptibility gene at IBD1 likely conferred susceptibility only 
for CD [67]. 
 
IBD-3, on chromosome 6p involving the major histocompatibility complex (HLA) has been 
implicated constantly for both CD and UC in various linkage studies. Data from linkage and 
epidemiologic studies estimate the contribution of the HLA region to overall genetic risk as 
64% to 100% for UC and 10% to 33% for CD [68]. Furthermore, this region contains the TNF 
gene, for which functional promoter polymorphisms affecting TNF expression have been 
reported [69]. Three promoter polymorphisms (in the -1031C, -863A, and -857T regions) have 
been found to be associated with susceptibility and progression of CD in a Japanese population 
and between CD and the -1031C allele in a European population [15, 70]. 
 
ATG16L1 and IRGM, these are two genes involved in autophagy, a mechanism for clearing 
intracellular components, including organelles, apoptotic bodies, and microbes [71]. In mice 
with low expression of ATG16L1, the morphologic features and gene expression of Paneth cells 
are abnormal. ATG16L1 carriers with CD also have abnormal Paneth cell morphology. In mice, 
ATG16L1 appears to regulate secretion of IL-1β and inhibit intestinal inflammation [8]. Short 
interfering (si)RNA studies have demonstrated that IRGM is required for mycobacterial 
immunity and may have an analogous role in the granulomatous response often observed in 
CD [9, 49].  
 
NADPH oxidase, it is a complex formed by several accessory proteins, that produces ROS and 
plays an essential role in cellular response in microbial invasion. Genetic mutations in genes 
encoding components of the complex, result in both X-linked and autosomal recessive forms of 
chronic granulomatous disease (CGD), which often develops in intestinal inflammation that is 
histologically similar to Crohn's colitis. A single nuclear polymorphism (SNP) within the first 
intron of NCF4 (encoding p40Phox subunit of the complex) was identified as a CD-specific 
susceptibility gene [71]. In a recent study Muise et al. reported a novel missense variant in 
NCF2 (encoding p67phox subunit) in patients with very early onset IBD, which results in 
neutrophil dysfunction and susceptibility to CD. In their study Muise et al. also described novel 
associations of the NADPH oxidase complex gene RAC2 with CD is associated with enhanced 
susceptibility to IBD [9, 56, 62, 72]. 
 
14 
 
IBD-5: SLC22A4 and SLC22A5, are two functional variants of the organic cation transporters 
ONCTN1 and ONCTN2, that have been associated with CD also in association with CARD15 
mutations [73]. Heterozygous carriage of the risk alleles increases the risk for developing CD 2-
fold, whereas homozygous carriage increases risk 6-fold [15, 62, 74, 75]. However some 
investigators are still hesitant to identify the mutations in these genes as causative of CD [2, 
56].  
 
DLG5, which encodes a scaffolding protein, is important in maintaining the epithelial structure, 
so any genetic variants in DLG5 could interfere with the epithelial barrier [56]. Two haplotypes 
of the DLG5 gene were found by Stoll et al. and have been associated with CD and UC. The 
variant 113G>A in association with CARD15 mutations in patients with CD has been confirmed 
[76].  
 
MDR1, the multidrug resistance gene variants have been associated with UC and CD [77, 78]. 
The MDR1 gene encodes P-glycoprotein 170, an efflux pump of amphipathic toxins, and is 
highly expressed at the apical surface of epithelia of the colon and distal small bowel. MDR1 is 
of particular attention because it has been linked with treatment-refractory IBD, and because 
MRD1-/-  mice do not develop colitis [79]. 
 
PPARG, polymorphisms were related with human CD [80]. PPARγ acts as a nuclear receptor 
that inhibits NF-κB activity and in active UC patients its expression is decreased [81]. 
Polymorphisms in PPARγ improve recruitment and retention of effector macrophages, 
neutrophils and T cells into the inflamed intestine [2]. 
 
MUC2, it is a major goblet-cell-derived secretory mucin and it is proven to be differentially 
expressed in human IBD, based in a study by Van der Sluis et al., where he reported that 
MUC2- /- mice display impaired goblet cells and develop spontaneous colitis, proving that MUC2 
cells have a critical role in colonic protection [82].  
 
2.3 Immune Response 
 Both CD and UC patients have activated innate (macrophage and neutrophil), acquired 
(B and T cell) immune responses and loss of tolerance to enteric commensal bacteria, either 
because of dysfunction in the primary or secondary mechanisms that normally drive and 
regulate such responses, or because of some dysfunction in the intestinal epi thelial barrier 
that leads to inappropriate penetration of microbial antigens [2, 6]. CD and UC are both 
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characterized by enhanced recruitment and retention of effector macrophages, neutrophils 
and T cells into the inflamed intestine, where they are activated and release pro-inflammatory 
cytokines. Accumulation of effector cells in the inflamed intestine is a result of enhanced 
recruitment as well as prolonged survival caused by decreased cellular apoptosis [2].  
 
2.3.1 Innate immune responses 
 Macrophages and dendritic cells in the lamina propria are increased in absolute 
number and have an activated phenotype in both forms of IBD, but have been studied in 
greater detail in CD. Production of pro-inflammatory cytokines and chemokines is enhanced in 
IBD, and expression of adhesion molecules and co-stimulatory molecules is also increased. 
Cells involved in innate immune responses are activated and the expression of most pro-
inflammatory cytokines and chemokines are upregulated in both CD and UC. Activation of NF-
κB stimulates expression of numerous molecules relevant to the pathogenesis of IBD. These 
include molecules involved in the inflammatory response, such as IL-1β, TNF, IL-6, IL-8 and 
other chemokines, ICAM1 and other adhesion molecules, and co-stimulatory molecules, 
including CD40, CD80, CD86 and the inducible T-cell co-stimulator ICOS. Expression of each of 
these pro-inflammatory molecules is increased in active IBD. By contrast, cytokines that induce 
TH1 and TH17 responses are selectively up regulated in active CD but not in UC. Selective 
inhibition of most of this cytokines attenuates the onset of experimental colitis [2]. Neutrophils 
cause tissue damage, which seems to be exacerbated in IBD patients due to an extended lifes-
pan from impaired apoptosis, through the release of nonspecific inflammatory mediators, such 
as reactive oxygen intermediates, lipid mediators and proteases, and secrete cytokines like IL-
1β and TNF-α [43]. 
 
2.3.2 Adaptive immune T cell responses 
 In contrast with what happens in the innate immune response, T-cell responses vary 
greatly between CD and UC, so they should be considered separately [4]. 
 
2.3.2.1 Crohn's disease  
 A variety of T-cell defects have been observed in IBD patients, this include, defective T-
cell apoptosis, which has been associated with a rapid cell cycle in CD; defects in regulatory T-
cell activation and function; and mouse models have demonstrated that both excessive pro-
inflammatory and deficient anti-inflammatory responses may manifest [43]. 
 Most mouse models present a similar cytokine profile to the one seen in the human 
disease. The Th1 traditional cytokine profile is dominant in patients with CD, and is mediated 
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by IFN-γ, the production of which is stimulated by IL-12, produced by antigen-presenting cells 
(APCs). CD can also present a Th17 cytokine profile, where IL-17 mediates Th17 responses. The 
production of this cytokine is stimulated by the production of IL-6, TGF-β and IL-23 by innate 
immune cells and APCs [43]. Additionally cytokines IL-27 and IL-21 are also increased in CD 
patients [2, 8, 9, 83]. 
 
2.3.2.2 Ulcerative Colitis 
 In UC there's also a range of T-cell defects that can be observed, defective T-cell 
apoptosis in UC has been associated with a slower than normal cell cycle and defects in 
regulatory cytokines, TGF-β or IL-10 are associated with the development of UC [43]. 
 This disease is considered to have a Th2 cytokine profile, but the concentrations of IL-4 
and IL-5 which are characteristically elevated in this type of response, have been variable in UC 
tissues. UC has been associated with the production of various autoantibodies, such as 
neutrophil cytoplasmatic antibody (pANCA) and anti-tropomyosin, which might be indicative of 
a Th2-mediated immune response. Studies on the production of immunoglobulin sub-classes, 
such as IgG1 and IgG4 predominate in UC.  So, this way UC is considered to have an atypical 
Th2-type response, mediated by NK T cells that secrete IL-13 [2-4]. 
 
2.3.3 Adaptive immune B-cell responses 
 B cells produce antibodies to both bacterial and nonbacterial antigens in mouse and 
human IBD. This supports the hypothesis that, there is a break down in mucosal tolerance. 
Several antibodies against microbial products are increasingly recognized in IBD, this include 
anti-Saccharomyces cerevisae (ASCA), anti-12, anti-Ompc and anti-flagellin antibody CBir1, 
being that 78% of patients react at least to one of these antibodies [8]. This implies that rather 
than a global loss of tolerance, different patients may form one or more specific antibodies, 
and the combinations present may help stratify disease subtypes [43]. 
 
2.3.4  Malfunction of the immune system 
 It is accepted that IBD results from an inappropriate response of a defective mucosal 
immune system. Experimental evidence from studies in vitro, in animals and in humans 
suggest that several pathways might result in inflammatory cascades triggered by the 
microbial antigens [20]. 
 First, the epithelial barrier is leaky in IBD patients. Several studies have shown a 
lowered epithelial resistance and increased permeability of the inflamed and non-inflamed 
mucosa in CD [84]. Defective regulation of tight junctions might one of the causes of increased 
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permeability [8, 11], it may be inherent or induced by infection or nonsteroidal anti-
inflammatory drugs [43]. The inflammatory response often results in continued epithelial 
injury, which causes erosions, ulcerations and a decrease in the production of defensins. It was 
shown that patients with CD exhibited an approximately 50% decrease in expression levels of 
α-defensin compared with controls [11]. The importance of the epithelial barrier in disease 
predisposition is supported by the finding of abnormal intestinal permeability in some first-
degree relatives with CD [9]. 
 Innate immune mechanisms of the epithelial layer are sometimes disturbed. Mucosal 
epithelial cells have a different pattern of TLR expression. TLR3 is significantly down regul ated 
in active CD. By contrast, TLR4 is strongly upregulated [85]. An upregulation of NOD2 in 
epithelial cells, has also been reported,  which might compromise the ability of the host to 
eliminate invasive and pathogenic microbes resulting in chronic inflammation [20]. 
Abnormalities of acute inflammation were found in patients with CD, these consisted of a 
failure of neutrophil accumulation and IL-8 production at sites of trauma in the bowel. These 
findings were not present in healthy controls. The problem with neutrophil accumulation in CD 
was shown to be due to the reduced secretion of IL-8 by macrophages [55]. 
 Animal and in-vitro studies suggested that, there might be a loss of tolerance to enteric 
bacteria inducing Th1 and Th17, pro-inflammatory immune responses [11, 20, 43, 67].  
 IBD patients have disturbed clearance of auto-reactive T-cell populations. Due to a 
failure of central (thymic) and peripheral tolerance, activated T cells persist and do not 
undergo apoptosis [20]. Defective mucosal T-cell apoptosis is possible to play a key play role in 
IBD, support for this theory comes from studies that investigated the Bcl-2/Bax protein family, 
where expression levels of Bax were clearly reduced in inflamed UC colonic epithelium[67].  
 Balance between effector and regulatory T cells is disturbed in IBD. When the disease 
is active, effector T cells (Th1 and Th2) predominate over regulatory T cells [20]. The release of 
reactive oxygen and nitrogen metabolites, cytotoxic proteins, lytic enzymes, and cytokines by T 
cells leads to exaggerated death of enterocytes and pathological inflammation of the host 
tissue [67]. 
 
2.4 Reactive Oxygen Species 
 Reactive Oxygen Species (ROS) have been largely studied from different perspectives, 
some think they are harmful and cause innumerous diseases, others think they are essential 
and conserved during our evolution and others think ROS should be kept in a very tight 
control.  
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 ROS are chemical oxygen species with one or more unpaired electrons that make them 
chemically reactive to other species. ROS include superoxide (•O2
-), the hydroxyl radical (•OH), 
the hydroperoxyl radical (•O2H), nitric oxide (NO
•), and singlet oxygen (O2) [86-89]. In the 
normal aerobic metabolism oxygen is the last receptor of electrons in mitochondrial 
respiratory chain, being in last term fully reduced to water. A small percentage of electrons do 
not travel to the end of the chain staying free to react with O2 and form 
•O2
- [86, 87, 89, 90]. 
However mitochondria is not the only precursor for ROS, there are oxidase enzymes like 
NADPH in phagocytic cells and arachidonic acid metabolizing enzymes (e.g. cyclooxygenase 
and lipoxygenase) that also produce superoxide that serves as predecessor for other ROS [87, 
91, 92]. 
ROS may play a far more integral role in the regulation of cellular and whole organism 
health, than was previously thought. It is becoming evident that under physiological 
conditions, ROS participate in crucial cellular events, functioning either directly as signaling 
molecules and/or indirectly by mediating global changes in the cellular redox status. Some of 
their down-stream targets include metalloenzymes and transcription factors that are sensitive 
to redox changes [89, 90, 93-95]. 
 
2.4.1 NADPH in ROS production 
 NADPH is a professional ROS producer, its role is only to produce ROS, and it is 
localized within the cell membrane being constituted by various subunits. In its constitution it 
has cytochrome b558, which consists of two subunits gp91phox (Nox2) and p22phox. Upon cell 
activation, two cytosolic regulatory subunits p47phox and p67phox, as well as two small G 
proteins Rac1 and 2 are translocated to the membrane and associated with the cytochrome 
b558 [86, 89, 91, 94]. 
This enzyme complex then generates superoxide by one-electron reduction of oxygen via 
its gp91phox subunit using reduced NADPH as the electron donor.  
NADPH oxidase is a distinct enzymatic source of cellular ROS generation, because this 
enzyme is a “professional” ROS producer [96], whereas the other enzymes produce ROS only 
as by-products along with their specific catalytic pathways [94].  
Several lines of studies have suggested that one important physiological function of 
NADPH oxidase in mammalian cells is the modulation of multiple redox sensitive intracellular 
signaling pathways by generating ROS molecules, including inhibition of protein tyrosine 
phosphatases, activation of certain redox-sensitive transcription factors, and modulation of 
the functions of some ion channels [94, 97].  
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Some authors think that certain stimuli like radiation, heavy metals and toxic chemicals 
lead to cellular stresses and suggest that NADPH oxidase may be an important component of 
the cellular stress signal transduction network. NADPH oxidase/ROS-mediated signaling might 
therefore represent a cellular “alarm system” that can alert the cells and prime them either to 
be adapted to the stress or to undergo apoptosis, being an ancient mechanism of multicellular 
organisms’ defense [91, 93]. 
Therefore, Nox-mediated redox signaling activation may have a critical role in coordinating 
the responses of the cell to deal with the adverse effects, either by activating stress kinases 
and promoting stress tolerance or by removing the seriously damaged cells by inducing 
apoptosis [89, 91].  
 
2.4.2 ROS in Immunity 
Nox-generated ROS can participate in immune function in a variety of ways, which are 
not mutually exclusive. First, the reactive oxygen itself or its by-products such as HOCl and 
peroxinitrite can directly oxidize biomolecules in invading microbes in a fairly non-specific 
manner, resulting ultimately in molecular damage and microbial cell death. Second, ROS can 
participate in signal transduction mechanisms linked to immunity and inflammation. This 
occurs through the selective oxidation of specific signaling enzymes/proteins that are linked to 
processes such as the secretion of cytokines or the activation of other killing mechanisms. Such 
signaling targets include transcription factors as NFk-B, signaling proteins such as protein 
kinases and phosphatases and ion and/or proton channels [93]. The first role to be definitively 
established for Nox-derived ROS was in innate immunity, mediated by professional phagocytes 
like neutrophils and macrophages [93]. In addition, macrophages produce large amounts of NO 
during phagocytosis; when NO reacts with superoxide, it generates the highly cytotoxic 
chemical species peroxinitrite (HONO) [93]. The activity of the phagocyte NADPH-oxidase also 
triggers opening of proton and potassium channels [93], that are proposed to change the ionic 
environment of the phagosome thereby activating microbicidal proteases and contributing to 
microbial killing [93]. Regardless of the precise mechanisms, it is clear from the inherited CGD 
that mutations resulting in defects in ROS generation by the respiratory burst oxidase are 
associated with an inability of phagocytes to kill bacteria and other microbes [93] convincingly 
demonstrating a role for the Nox2 system in innate immunity mediated by professional 
phagocytes [93, 98]. 
Neutrophils are the first line of defense with highly efficient bactericidal and tissue -
toxic mechanisms in host protection including the phagocytosis of opsonized particles, 
degranulation with release proteases and the production of ROS. Among these functions, 
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production of reactive oxygen intermediates (ROIs), known as respiratory burst, is especially 
important in microorganism killing. Considering that efficient phagocytosis and the subsequent 
production ROIs play an important role in the intracellular killing of microorganisms by 
phagocytes, defects in one or both of these functions may lead to a deficiency in phagocytic 
function [98, 99].  
So, undoubtedly ROS are essential for immune response and for its action destroying 
pathogens, there are opinions that its deregulation leads to oxidative stress and consequently 
to disease. However there are examples like CGD where dysfunctional ROS production leads to 
high inflammation levels and many complications.  
 
2.4.3 ROS Imbalance  
 ROS has to be kept under very straight concentrations, if there is an imbalance 
between ROS production and scavenging we are towards oxidative stress. Situations like this 
might happen because of antioxidant decrease (e.g. mutations in antioxidant enzymes like 
superoxide dismutase, glutathione peroxidase) and ROS over-production (e.g. excessive 
activation of ROS producers) [86, 89]. This homeostasis is essential to healthy function, 
otherwise increasing scavenging mechanisms can occur, for example: tissue injury because of 
lipid peroxidation, DNA and protein damage or in last term cell death by apoptosis or necrosis 
[86]. 
ROS can start to interact with DNA, lipids, proteins and those interactions can lead to 
diseases like cancer, heart disease and many others [86]. For example lipids oxidation can 
occur in the presence of free oxygen radicals, leading to the formation of hidroperoxides and 
lipid peroxides. Lipid peroxides and oxygen radicals are responsible for many of the damaging 
reactions in the cell. They stimulate the peroxidation reactions that are toxic to cells and cell 
membranes. They can damage biological membranes, make the membrane leaky, and 
eventually cause complete membrane breakdown [86, 87]. Another redox-sensitive 
transcription factor is p53. It was demonstrated that oxidation of p53 alters its conformation 
and disrupts its DNA binding activity, resulting in a pattern change of p53-dependent gene 
expression. Moreover, p53 was shown to act as a homeostatic regulator by lowering ROS 
levels in stem cells and controlling hematopoietic stem cell self-renewal. Finally, the NF-kB 
signaling pathway is also significantly altered by deregulated ROS. ROS activates NF-kB 
signaling through elimination of the IkB inhibitor [89]. An increase in ROS levels induces the 
activation of the IkB kinase (IKK), which in turn phosphorylates IkB, leading to its proteasome-
dependent degradation [92, 100]. 
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2.4.4 ROS in Disease  
 Regarding the importance of redox in regulating crucial cellular events, the presence of 
oxidative stress means that there are oxidative perturbations, that if not corrected could result 
in a disease state. Cancer, cardiovascular disease, and metabolic disorders such as metabolic 
syndromes are the leading causes of death worldwide, with the number of cases for each 
condition projected to increase substantially over the next few decades. Cancer is an - example 
of a complete disarray of cellular redox homeostasis. Unlike metabolic disorders, both 
oxidative and reducing cellular environments appear to play a role in carcinogenesis. Oxidative 
imbalances may trigger a multitude of molecular and cellular events induced by the ROS [89, 
90]. 
 
2.4.4.1 Inflammatory Bowel Disease  
 Oxidant stress is a major factor in IBD. It is been described that IBD patients have an 
enhanced production of reactive oxygen metabolites by epithelial and phagocytic cells 
(neutrophils, monocytes and macrophages) that leads to an increased oxidative stress in 
mucosal tissues [87, 101, 102]. It is stated that monocytes and polymorphonuclear cells in IBD 
are activated and produce high levels of pro-inflammatory mediators such as leukotriene B4 
(LTB4) or platelet activating factor (PAF) leading to the release of large amounts of potentially 
cytotoxic reactive oxygen metabolites demonstrated through in situ quantification and 
through evaluation of lipid peroxidation [87, 101, 103, 104]. This was also related to the 
augmented migration of neutrophils and macrophages into the bowel mucosa, higher levels of 
ROS and the degree of inflammation and tissue damage [87, 101]. It is been showed that not 
only there is an increased oxidative stress in mucosa but also a decrease of antioxidants, with 
low blood levels of vitamin C and vitamin E, low levels of CuZn superoxide dismutase (SOD), 
glutathione peroxidase, catalase, vitamin A and β-carotene, thus leading to an increased 
oxidative state [87, 102]. Clinical data have shown that the administration of bovine CuZnSOD 
leads to an attenuated mucosal inflammation and injury in Crohn’s patients [87, 105]. It is also 
acknowledged that the use of sulfasalazine (SAZ), mostly known by its commercial name 5-
ASA, is beneficial in CD by inhibiting cyclooxygenase and lipoxygenase activities, and interacts 
with the superoxide, suppressing the formation and promoting of the degradation of free 
radicals, therefore protecting from oxidative stress-induced mucosal injury and inflammation 
[87, 106, 107]. 
 Pavlik et al say that besides ROS overproduction, NADPH is not involved in it, once that 
inhibiting it made no alteration in the susceptibility of mice to DSS-induced colitis, indicating 
that NADPH oxidase is not involved in the pathophysiology of this model of UC [108]. Leoni G. 
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et al demonstrated that epithelial ROS induce a pro-resolution of epithelial wound closure, by 
mediating Anexin 1 (anti-inflammatory protein) production that control excessive immune cell 
trafficking by many mechanisms, one of them neutrophil influx inhibition and apoptosis at 
resolving inflammation site [109]. So, the effective role of ROS in IBD is still not clear, however 
new lines of thought consider that ROS has a resolution role in IBD.  
 Inflammation is associated with the production of ROS as a probable cause of 
neoplasic evolution [110]. ROS is being reported to be cause of DNA alterations through the 
augmentation of 8-hydroxyguanine (8-OHDG) production [102] in CD. In another study by 
D’Inca et al on UC, the high levels of 8-OHDG correlated with higher levels of ROS lead to an 
accumulation of oxidative DNA damage alongside with the progression of the disease and 
correlates with higher dysplastic lesions and possible implications for mutagenic and 
carcinogenic progression [111]. It is already being demonstrated that IBD patients can have a 
defective neutrophil respiratory burst [112, 113]. Despite early reports from genome-wide 
association studies (GWAS) indicating the NCF4 gene as susceptibility gene for CD [71, 114] a 
recent GWAS study did not corroborate these results [115]. Even so, in a study by Muise et al 
they not only replicate the association of NCF4 with CD previously described but also 
illustrated a novel associations of the NADPH oxidase complex gene RAC2 with CD and 
introducing a novel missense variant in NCF2 with very early onset IBD that leads to an 
neutrophil dysfunction and susceptibility to CD, thus indicating that the NADPH oxidase 
complex genes play a role in the pathogenesis of CD [116]. 
 
2.5 IBD-associated colorectal cancer animal models 
 Cancer is a growing health problem around the world and is one of the major causes of 
death after heart disease [117]. Nowadays there are over 10 million cases of cancer each year, 
being colon-cancer one on the top of the list [118, 119]. In the past decades studies on CRC 
have shown that its incidence has been increasing, becoming one of the most common and 
lethal cancers in Western countries [120] and this problematic is also a growing concern to 
Asian nations [121].  
 Colorectal cancer (CRC) development is the most serious complication associated with 
longstanding IBD. Increasing risk causes are the duration of the disease and the extent of 
colorectal involvement. Cancer development follows a sequence of no dysplasia, indefinite 
dysplasia, low-grade dysplasia, high-grade dysplasia and carcinoma. In IBD patients neoplastic 
lesions arise within areas of the mucosae that have been involved with colonic inflammation 
[122]. 
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 Currently there are many animal models for study IBD, but only a small number of this 
are appropriate to study the dysplasia cancer-sequence. The most widely used mouse model is 
with DSS. In most studies, normally to successfully induce a carcinogenic path is usually 
needed a long period with multiple cycles of DSS-induction, or the use of carcinogenic 
coadjuvants to diminish the exposure periods. Cooper HS. et al. described a four-cycle DSS 
induction to be associated with the development colitis-associated dysplasia and 
adenocarcinoma, with dysplasia incidence of 13.9% at 12 week of treatment [123]. Other 
studies combine DSS induction with a colon carcinogen promoter to achieve a higher incidence 
of colonic tumors in lesser time. Tanaka T. et al. and others demonstrated through the use of 
azoxymethane (AOM) plus DSS that, the amount of time needed to promote colon 
carcinogenesis in mice could be reduced, despite the treatments resulted in high incidence of 
colonic neoplasms it still took 20 weeks [124]. One hundred percent of colonic tumorigenesis is 
achieved when compared to 15%-20% when DSS is administered alone. Although results also 
showed that mice receiving only AOM did not developed dysplasias, suggesting that the dose 
of carcinogen used is insufficient to induce dysplasic lesions in absence of inflammation caused 
by DSS [125]. In a similar way the use of different heterocyclic amines have been proved to be 
important food-derived carcinogens with ability to promote colon-neoplasia when associated 
to DSS- induced colitis [124, 126]. Clapper ML et al. in their review mentioned that the 
existence of determined mutations like APC+/Min in association with DSS treatment accelerate 
the formation of colitis-associated dysplasia's and their progression to invasive cancers [127]. 
Other important colitis-associated dysplasia mutation is the p53 gene, described in the work of 
Hussain SP. et al. Loss of p53 function is an early and critical event in colitis-associated 
colorectal cancer, and DSS-treated p53-/- mice have significantly more lesions (cancers and 
dysplasias) when compared to their non-mutated counterparts [128-130]. In a study focusing 
in mouse-models related to the inflammation and colitis-associated dysplasia, Sturlan S. et al. 
showed that IL-10 -/- mice spontaneously develop colitis which eventually leads to high grade 
dysplasias culminating in adenocarcinoma in tender age [131, 132]. They also observed high 
similarities in the histopathological pattern of colorectal cancers between IL-10-/- and IBD-
associated carcinomas in humans [131]. Chemically-induced tumor incidence, transplanted 
tumor growth and lung foci formation are increased in IL-10−/− mice [133]. More specifically 
Betra et al. showed how AOM and DSS treatment promotes inflammation mediated colonic 
tumor growth in IL-10 KO mice [134]. Patients with mutated IL-10 signaling systems show early 
and aggressive development of systemic inflammation including IBD [132]. The development 
of adenocarcinoma in IL-10 KO mice seems to be associated with colonic bacterial infection, 
this causes injurious leakage of bacterial antigens into the mucosa, which causes an immune 
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response that in turn leads to the development of IBD and subsequently adenocarcinoma in 
the host [135]. Seamons A. et al. utilized DSS to induce inflammation and cancer without the 
use of an additional carcinogen, in TGF-β signaling-deficient Smad3-/- mice [136, 137], which 
are defective in one of the most common signaling pathways mutated in human colorectal 
cancer [138]. Previously they have demonstrated that development of colitis and colon cancer 
in Smad3-/- mice requires a trigger, such as infection with enterohepatic Helicobacter, to 
induce disease, and others have shown that DSS serves as a chemical trigger to induce colon 
cancer in Smad3-/- mice [139]. Regarding iNOS in carcinogenesis there have been several 
debates about its play in the pathology. It is well known that in patients with UC iNOS levels 
are overexpressed relating with a path to carcinogenesis [140-145]. Although Seril D. et al. 
introduces to this problematic in his work, using iNOS knockout mice, in a DSS-colitis 
associated carcinogenesis model, he demonstrated that there was no significant differences 
when compared iNOS-/- mice with the WT, this way reducing the importance of iNOS in the 
pathology and at the same time left indications that eNOS (endothelial NOS) could have a 
significant place in the pathology. In the same way other researchers focusing in iNOS 
deficiency/inhibition on experimental carcinogenesis also demonstrated a multiplicity of 
results. Rao CV. et al. attenuated an AOM-induced colon-carcinogenesis using a iNOS specific 
inhibitor [146]. Also using an APCmin/+ mice model the use of aminoguadinina NOS inhibitor and 
L-arginine deficient, exhibited decreased colon-carcinogenesis [147], being also reported by 
Kisley et al. 2002 that iNOS knockout mice model are resistant to carcinogenesis tumor lung-
cancer [148]. However, another study by Scott DJ. et al. reported a slight enhanced in colon-
carcinogenesis development in APCmin/+iNOS-/- [149]. 
 
2.6 Phenolic-acid derivatives 
  Nowadays innumerous cancer-treatments are available, nevertheless they still remain 
insufficient to treat/eradicate most cancers and/or inhibit cancer metastasis. Therefore, 
research for novel anticancer agents that are highly effective, with low toxicity improving the 
disease condition is constantly increasing [150]. A novel generation of natural products offers 
opportunities for innovation and discovery of new therapeutics. Natural products play a major 
role in cancer prevention and treatment, and currently a considerable number of this natural 
antitumor agents is already being used [151]. The protective effects against cancer found in 
the natural dietary compounds are believed to be due to the induction of cellular defense 
systems (detoxifying and antioxidant enzymes system), inhibition of anti-inflammatory and cell 
growth signaling pathways, culminating in cell cycle arrest and/or cell-death [152].  
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 Natural compounds as plant polyphenols are always present in a diet rich in vegetables 
and fruits and are considered to be serious candidates for being responsible for cancer 
protective effects [153]. Dietary polyphenols are mainly consumed through fruits and 
beverages (juice, wine, tea, coffee and beer), apart from vegetables, cereals and olive 
derivatives, food components mainly associated to the mediterranean diet [154]. Polyphenolic 
compounds are a heterogeneous  group of compounds that have been categorized based on 
their structure in phenolic acids and analogs, stilbenes, flavonoids and analogs, miscellaneous. 
 Propolis, is a natural resinous substance collected from trees by Apis mellifera honey 
bees by collecting resins and changed by the action of enzymes contained in their saliva [155-
157]. Propolis has long being used in traditional medicine [158] and has been reported to have 
a broad spectrum of biological activities such as, anti-inflammatory, antioxidant and antitumor 
[158-161], due to its list of constituents, where we find 2-20% of caffeic acid (CA) and its esters 
[162], which are important phenolic acids with innumerous health benefits.  Caffeic acid ester 
derivatives present in propolis are more lipophilic than CA and thus easily facilitate their entry 
into the cell, and also require small amounts to exhibit their effective inhibitory activities [163]. 
 In 1993 Frenkel, Wei et al. worked on the antitumor/anti-inflammatory activity of 
propolis, showing that caffeic acid phenethyl ester-CAPE (synthesized by esterification of CA 
[164]) was a potent inhibitor of a number of oxidative processes at very low doses both in vitro 
and in vivo [165]. Jaganathan, Mandal et al. study in honey revealed that the sample exhibiting 
the highest phenolic concentration showed the best protective effects against oxidant-induced 
cell death [166]. Since the potential utility of caffeic acid ester derivatives in tumor inhibition, 
Rao Desai and its team studied the antimutagenic and antitumorigenic activities of several 
synthesized caffeic acid esters, were they significantly inhibited the growth of human colon 
HT-29 and HCT-116 cells and the activities of ODC (ornithine decarboxylase) and TPK (tyrosine 
protein kinases) at much lower concentrations when compared to CA. Results demonstrated 
that caffeic acid esters possessed antimutagenic activity against DMAB-induced mutagenecity 
in Salmonella typhimurium strains TA98 and TA 100 [167]. In a follow up study Rao Desai et al. 
presented results on how the same caffeic acid esters derivatives present in honey possessed 
inhibitory activities against AOM-induced colonic ODC, TPK, and lipoxygenase activities and 
ACF formation, which are relevant to colon carcinogenesis [168]. The mechanisms of CA-
induced apoptosis in colon cancer cells, was later studied by Jaganathan, Mandal et al.  where 
CA notably inhibited HCT15 colon cancer cell proliferation in a dose-dependent manner. CA 
treatment increased the number of cells in sub-G1 phase of cell cycle, which indicates 
apoptosis [169]. CA inhibited colony formation similar to some anticancer agent like Triphala 
(TPL) [121]. In 2012 Dev-Aur Chou and its team reported the anticancer effects of caffeate 
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derivatives in COLO 205 human colon cancer cell line. Decyl caffeate induced apoptosis in 
COLO 205 cells through both Fas- and mitochondria-mediated pathways [170]. Research by 
Banskota, Nagaoka et al., using Netherlands propolis MeOH extract showed antiproliferative 
activity against highly liver-metaststic murine colon 26-L5 carcinoma cells [158]. Those results 
led the team to continue the research and further investigate the structure-activity 
relashionship of CAPE and twenty synthesized CAPE-analogues and examine their 
antiproliferative activities in six tumor cell lines, showing that of all the tested cell lines CAPE 
analogues possessed selective antiproliferative activity toward liver-metaststic murine colon 
26-L5 carcinoma cell line [164]. The same CAPE-analogues also inhibited tumor nodules and 
metastasis in lung cancer [171]. Lee, Liao et al. reported the effect of nine synthesized CAPE-
like analogues for investigating the growth of human neck cancer, revealing that CAPE and its 
ethyl analogues were considerable cytotoxic [172]. Previous studies on how CA significantly 
offers protection against UVB-induced erythema in humans and UVC-induced in cell lines [173, 
174], justified a scientific investigation into the possible potential use of CA as a protective 
agent against UVB radiation-induced skin damages. Staniforth, Chiul et al. findings suggested 
that CA may prevent UVB-induced immune suppression by inhibiting IL-10 expression. While 
CA inhibition of UVB-induced MAPK signal transduction pathways and downstream 
transcription factors AP-1 and NF-kB may confer protection against photocarcinogenesis [175]. 
Kudugunti, Vad. and its team studied the effect of CAPE as anti-melanoma agent in skin tumor 
model of melanoma in C57BL/6 mice and found it to cause significant tumor growth inhibition 
when in B16-F0 melanoma cell line with minimal toxicity [176]. Research done on the role of 
CAPE and how it interacts with tumor necrosis factor (TNF), revealed that CAPE completely 
blocks activation of NF-kB by TNF in a dose-and time-dependent manner and the activation of 
NF-kB by other inflammatory agents is also blocked [177]. Few years later Mirella Nardini 
reported the effect of CA on Cer (ceramide)-induced NF-kB activation and apoptosis in the 
human monocytic U937 cells, the results indicated that very low concentrations of CA 
modulate Cer-triggered signal transduction pathway, including NF-kB activation and apoptotic 
response in U937 cells [178]. Further studies in which the effects of CAPE on iNOS expression 
and iNOS enzyme itself activity were examined, elucidated that CAPE is an inhibitor of LPS and 
IFN-ϒ-induced NO production whose action is mediated by inhibiting iNOS gene transcription 
via action on the NF-kB site is the iNOS promoter as well as by directly inhibiting the catalytic 
activity of iNOS [179]. With regard to the synthesis of PGs, Masferrer et al. showed that CAPE 
inhibits TPA- and carrageenan-mediated induction of COX-2, directly inhibits the activities of 
COX-1 and COX-2, and inhibits the release of arachidonic acid from membrane phospholipids 
[180]. The effects of caffeic acid ester derivatives were studied on NO production in murine 
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macrophages RAW264.7 cells by koji Uwai et al. Several compounds with various lengths and 
forms of the alcoholic alkyl side chains were arranged and the results revealed that their 
inhibitory effect on NO was dependent on the lenght and size of the side chain [181]. 
Investigation on the cytotoxicity of novel lipophilic caffeic and freulic acid derivatives in human 
breast cancer cells also concluded that an alkyl chain through an ester or an amide bond on 
both caffeic and freulic acid increases the cytotoxicity toward the cancer cell line [182]. Further 
research on cancer angiogenesis relationship with CA and its derivatives revealed an inhibition 
in tumor growth and angiogenesis process by inhibition of STAT3 activity, expression of HIF-1α 
and VEGF in a mouse xenograft model [183]. 
 
2.7 Objectives 
 The present work aimed to study how the lack of ROS influenced chronic DSS-induced 
colitis and disease evolution to colon-adenocarcinoma in Ncf1-deficient and WT B10.Q mice. 
Afterwards, the quality of the results on the animal model have provided the basis for a follow-
up project, where it was intended to unveil the synergies between the immune system and 
caffeic acid-based drugs in a combined therapy for colon-adenocarcinoma. 
 To achieve the proposed goals we: 
 Evaluated the clinical evolution of experimental colitis; 
 Evaluated the histopathological evolution of colitis; 
 Cultured peripheral blood mononuclear cells with caffeic acid-derivatives; 
 Cultured human colon-adenocarcinoma cell lines with caffeic acid-derivatives. 
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3.  Materials and Methods 
 
3.1 Animals 
 Female and male 6-8 weeks old homozygous Ncf1-mutant (BQ.Ncf1m1J/m1J, abbreviated 
Ncf1*, n=30) and wild-type (WT, n=30) B10.Q mice (C57BL/10 expressing H-2q) were obtained 
from breeding heterozygous mice followed by genotyping, as previously described [184]. 
Animals were bred and maintained under standard conditions, with food and water ad libitum 
in a specific pathogen–free environment. All animal studies were approved by the internal CNC 
Ethics Committee, and were in accordance with EU legislation for experimental animal welfare. 
 
 3.2 Induction of colitis 
 Colitis was induced by oral administration of 3% (w/v) DSS (average 40,000 g/mol, 
AppliChem, Darmstadt, Germany) in the first induction cycle and 2.5% (w/v) DSS in the second 
cycle ad libitum in drinking water. Reduction of DSS concentration was to avoid premature 
death. Two different colitis-induction protocols were used (Fig.1): Protocol 1 (P1)- mice were 
submitted to 7 days DSS- induction, followed by 21 days of resting on normal water. Protocol 2 
(P2)- mice were submitted to 7 days of DSS-induction, followed by 14 days of resting on 
normal water and a second 7 days DSS-cycle. Five Ncf1* and WT mice were sacrificed at the 
end of each time point: before the experiment had started and at days 22 and 30. Tissues were 
collected for histopathological analysis and assessment of colon lenght and spleen weight. 
 
Fig.1 Schematic overview of DSS treatment plan. P1) Protocol 1: one week of DSS- induction, 
followed by 3 weeks of recovery. P2) Protocol 2: one week of DSS-induction, followed by 2 
weeks of recovery and a second week of DSS- induction. Crosses (ƚ) indicate time-points where 
the mice were sacrificed.  
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3.3 Clinical evaluation of colitis 
 Animals were monitored every 2 days for alterations of colitis-related clinical scores: 
weight loss, diarrhea, colorectal bleeding and survival. Blood and stools scoring was performed 
as previously described [185]. Blood scoring: 0- no blood; 1- visible blood; 2- rectal bleeding. 
Stool consistency scoring: 0- Normal; 1- Soft but formed; 3- very soft; 4- diarrhea.  
 
3.4 Histopathological evaluation of colitis 
 Swiss rolls for the whole colon, rolled from the rectum to the cecum, were formalin 
ﬁxed, paraffin embedded and sections were hematoxylin/eosin (HE) stained according to 
standard protocols. 
  Inflammation was scored for proximal and distal segments regarding the number of 
inflammatory foci: 0- no inflammatory focus; 1- one inflammatory focus; 2- two inflammatory 
foci; 3- three or more inflammatory foci. Lymphocytes, plasma cells and neutrophils infiltration 
was scored based on cell morphology, with approximate percentage validation of each subset 
within the total observed inflammatory cells in inflammatory foci.  Epithelial morphology was 
scored based on the presence of tubular and villous hyperplasia, either as glandular 
hyperplasia above the muscularis mucosae or as formation of superficial villous projections, 
respectively. Dysplasia was scored in the same segments using a semi-quantitative scale 
according to the WHO 2010 guideline for colon adenocarcinoma classification [186]: 0- no 
dysplasia; 1- hypercromatic nuclear pluristratification and lamina propria separated glands; 2- 
epithelial low grade dysplasia (complex ramified glands with cell hyperplasia and pluristratified 
hypercromatic nuclei); 3- epithelial high grade dysplasia (beyond low grade dysplasia, nuclear 
atypia and mitosis).  
 
3.5 Caffeic acid-derivatives 
 Four caffeic-acid derivatives were used, ferulic acid (FA), feruloylhexylamide (FAHA) , 
caffeoylhexylamide (CAHA) and caffeic acid (CA) (Fig.2), they were synthesized as previously 
described [187], and ressuspended in Dimethyl sulfoxide (DMSO, Sigma Aldrich) to achieve 
4mM. The compounds were kindly donated by the Drug Discovery group from Faculty of 
Pharmacy University of Coimbra.  
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3.6 Cell culture  
3.6.1 Peripheral Blood Mononuclear Cells (PBMCs)  
 PBMCs were lysed with 1x RBC lysis buffer (NH4Cl 0.15M, KHCO3 10mM, EDTA 
0.1mM), for 10min and then centrifuged at 1250rpm for another 10min, the process was 
repeated twice. Supernatant was discarded in between steps. Cell suspension was then 
washed with 1x phosphate buffer saline (PBS), ressuspended and cultured in RPMI medium (L-
glutamine 2mM, HEPES-NA 10mM, penicillin 100U/mL, streptomycin 100ng/mL), 
supplemented with 10% heat-inactivated foetal bovine serum (FBS) at 37ο C in a humidified 
atmosphere containing 5% CO2. An average of 250,000 cells/mL were plated for each well. 
Chemical compounds to be tested, CA, CAHA, FA and FAHA were added to the multiwell 
immediately after the cell suspension was plated, in increasing concentrations of 10μM, 50μM 
and 100μM. Wells only with cell suspension and DMSO were used as negative controls. After a 
6 hours incubation period, 20μL of the anti-body mix (detailed below) was added to each well. 
Cell suspension was incubated for 30min at 4oC in the dark. Subsets of T cells and B cells were 
determined by flow cytometry. 
 The above process was repeated a second time. Cell suspension was cultured in 12h 
and 24h incubation periods. Only FA, FAHA and CAHA compounds were added in increasing 
concentrations of 50μM, 100μM, 150μM and 200μM. 
 
3.6.2 Human colon adenocarciona cell lines 
 To study the cytotoxicity of the synthesized compounds, in vitro studies were 
performed in two human colon cancer cell lines, namely C2BBe1 and WiDr.  
Fig.2 Chemical structure of the caffeic-acid derivatives. A) Ferulic acid (FA); B) feruloylhexylamide (FAHA); 
C) caffeoylhexylamide (CAHA) and D) caffeic acid (CA). 
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 C2BBe1 (brush border expressing) cell line was cloned from the Caco-2 cell line. The 
clone was selected on the basis of morphological homogeneity and exclusive apical villin 
localization. C2BBe1 cells form a polarized monolayer with an apical brush border (BB) 
morphologically comparable to that of the human colon. Isolated BB contained the microvillar 
proteins villin, fimbrin, sucrase-isomaltase, BB myosin-1 and the terminal web proteins fodrin 
and myosin II. These cells express substantial levels of BB myosin I similar to that of the human 
enterocyte [188]. 
 WIDr cell line has been shown by DNA fingerprinting to be a derivative of HT-29, 
although deposited with the ATCC as a colon adenocarcinoma line. WIDr cells are negative for 
Colon Antigen 3 expression, are positive for keratin by immunoperoxidase staining. The cells 
expressed p53 antigen (the p53 produced has a G -> A mutation resulting in Arg -> His at 
position 273). Growth of WiDr cells is inhibited by TNF-α. Inhibitors of dihydrofolate reductase 
are highly cytotoxic to WiDr cells [189]. 
 Cells were cultured in an adherent way according to American Type Culture 
Collections’ instructions. Both cell lines were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM, Sigma-Aldrich) and supplemented with 5% foetal bovine serum (FBS), 1% antibiotic 
and 0.25mM sodium pyruvate for DMEM. Cells were maintained at 37 ºC in a humidified 
atmosphere with 95% air and 5% CO2.  
3.7 Clonogenic assay 
 Clonogenic assay was used to study the effectiveness of CA, CAHA, FA and FAHA in cell 
survival and proliferation. One of the main features of cell death by apoptosis is the 
redistribution of fosfatildilserine, that in apoptotic cells binds to Annexin V (AV). Propidium 
Iodide (PI), which does not permeate viable cells, binds to DNA intercalating between the 
bases in late apoptotic and necrotic cells. Apoptosis is determined by flow cytometry by 
quantitation of the levels of phosfatidilserine in the outer membrane of apoptotic cells. 
Simultaneous use of AV and PI allows to distinguish between apoptosis and necrosis.  
 The above process using PBMCs was repeated. The chemical compounds CAHA, FA and 
FAHA were added to cell suspensions in concentrations of 200μM for CAHA and 150μM for FA 
and FAHA. Cell suspension was incubated for 24h. After 24h multiwell plates were centrifuged 
at 1500rpm for 5min and RPMI medium was carefully removed and replaced by fresh one. Cell 
cultures incubated for 4 days. After 4 days cell cultures were ressuspended and centrifuged at 
2500rpm for 5min. Supernatant was discarded. 100μL of 1x binding buffer (eBioscience) was 
added, followed by 2.5μL of Annexin-V (BD Bioscience), 1μL PI (Sigma Aldrich). Cell mixture 
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was incubated for 15min at RT. Then 150μL of 1x binding buffer was added. Samples were 
analyzed by flow cytometry. 
 
3.8 Cell proliferation assay 
 In order to evaluate cell proliferation in compound-treated and untreated cells, 
sulforhodamine B (SRB) assay was used. Cells were seeded in 48-well plates at a concentration 
of 50,000 cells/mL. After 24 hours, cells were treated with the vehicle of administration, 
DMSO, or with increasing concentrations (10µM to 200μM) of CAHA for 24 hours. After the 
incubation period, SRB assay was performed.  
 SRB is a colorimetric assay that consists in the electrostatic binding of the 
sulforhodamine B to the aminoacids, and represents a measure of cell proliferation based on 
the total protein content. For that, cells were washed two times with PBS and fixed with a 
freezing solution of 1% acetic acid in methanol, at 4ºC. After one hour of incubation, cell s were 
allowed to air-dry. Then 100μL per well of SRB 0.4% (in 1% acetic acid solution) were added 
and the plate incubated in the dark at room temperature, for 1 hour. Excess dye was removed 
and the plates allowed to dry. To solubilize the protein bound-dye, 10mM Tris base solution 
(pH10) was added to each well. Absorbance was measured at 540nm using a reference filter at 
690nm. The cytotoxicity was expressed as percentage of cell proliferation in relation to the 
control experiment, namely, cultures treated with the vehicle of administration. Each 
experiment was performed in triplicate and repeated in at least two independent experiments. 
 
3.9 Enumeration of T and B cell subsets  
 In order to differentiate cell subsets, peripheral blood samples were labeled with 
surface anti-human monoclonal antibodies (mAbs). T cells were labeled with anti-CD4 FITC 
(clone: OKT4) or anti-CD4 PE (clone: OKT4), anti CD8 APC (clone: SK1), anti-CD25 PerCP-Cy5.5 
(clone: M-A251) and anti-CD69 PE (clone: FN50) or anti-CD69 FITC (clone: FN50). B cells were 
labeled with anti-CD19 PerCP-Cy5.5 (clone: HIB19), anti-CD69 FITC (clone: FN50), anti-CD80 
APC (clone: 2D10), anti-CD1d PE (clone: 1B1). All mAbs were purchased from BioLegend (San 
Diego, CA, USA), BD Bioscience (San Jose, CA, USA) and eBioscience (Frankfurt, Germany). 
 PBMCs were incubated with 30μL of mAbs mix (diluted 1.5:100 in 1x PBS). 
 
3.10 Flow cytometry analysis 
 The analysis was performed using a six-parameter, four-color FACSCalibur flow 
cytometer (Becton Dickinson, San Jose, CA, USA) equipped with a 15-nW argon laser. For each 
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assay, events were collected using Cell Quest software (Becton Dickinson) and analyzed using 
FlowJo X 10.0.7r2. 
 
3.11 Flow cytometry evaluation of T and B cell subsets 
 Using Flow Cytometry B and T lymphocytes subsets could be evaluated by the 
differential surface expression of some markers: T helper cells (CD4+), cytotoxic T cells (CD8+), T 
effector cells (CD4+CD25+ and CD8+CD25+, which include regulatory Treg cells) and activated T 
cells (CD4+CD69+ and CD8+CD69+); B lymphocytes (CD19+), B regulatory cells (CD19+CD1d+), late 
phase activated B cells (CD19+CD80+), early phase activation B cells (CD19+CD69+), (Fig.3 A-B). 
 
 
 
 
 
 
 
 
 
A 
B 
Fig.3 A) Representative dot plots of T lymphocytes and its subsets. B) 
Representative dot plots of B lymphocytes and its subsets. 
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3.12 Statistical analysis  
 Statistical tests were performed using GraphPad Prism Version 5.0 software (CA, USA). 
Since data did not follow a normal distribution the non-parametric Mann-Whitney and 2way 
ANOVA test was used to compare values between groups and time-points. Differences were 
considered significant for p<0.05. 
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4. Results 
 
4.1 Clinical evaluation of DSS-induced colitis 
Weight-loss was continually monitored throughout the entire study (Fig.4 A). At 
baseline the weight of Ncf1* and WT mice was comparable (WT=29.8±3.90g, 
Ncf1*=31.3±3.9g). Weight loss began on day 3 for the mice undergoing both DSS-induction 
protocols. At day 13, during the recovery period, all animals reached the minimum weight with 
Ncf1* mice presenting a significantly greater loss than WT. Weight recovery went all the way 
through day 30 for those mice in P1, with WT recovering the baseline weight whereas Ncf1* 
reached only up to 90% of the original weight. Those mice under P2 had a renewed weight loss 
starting on day 22 which went on until day 30, with Ncf1* mice presenting significantly greater 
loss than WT (Ncf1* reached 75% of baseline weight vs WT reaching 90% of baseline weight).   
  
Stools consistency and the presence of blood in the feces are two further clinical signs 
of DSS-induced colitis [185]. Therefore, as with body-weight, mice were monitored for changes 
in stools throughout the study. During the 1st induction period (Day 0 through Day 7), both 
Ncf1* and WT groups had an accentuated decrease in stool. During the resting period both 
groups started to recover regarding the two clinical parameters. WT and Ncf1* mice submitted 
to P2 presented a new surge in anal bleeding as well softer stools which were significantly 
different for the clinical symptoms in those animals undergoing P1 (Fig.4 B and C).  
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Fig.4 Ncf1* mice presented severer clinical scores than their WT counterparts. A) Mice weight 
distributions and analysis for all experiment. In experiment, average weight  ± SE, (baseline weight:  
WT=29.8±3.90g, Ncf1=31.3±3.9g). B) Mice stool consistency scoring. C) Analysis of rectal blood presence ± 
SE. Weight, stool consistency and blood presence scorings are detailed in methods section. Asterisks 
indicate p<0.05, double asterisks p<0.001, triple asterisks p<0.0001. Mann-Whitney test was performed 
between each group, Ncf1* control/WT control; Ncf1 */WT; Ncf1* Rec/WT Rec; Ncf1*/Ncf1* Rec; WT/WT 
Rec. 
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Other parameters normally evaluated in this studies, are the colon's length and 
spleen's weight. The colon's shortening and the increase in spleen's weight as a consequence 
of a DSS induction are well known facts.  
In both protocols the two mouse groups presented a significant reduction of colon’s 
length after colitis induction (WT: D0 vs D22 p= 0.0159; Ncf1*: D0 vs D22 p= 0.0102). The 
length of the colon in both groups of P1 mice at day 30 remained equivalent to day 22, 
whereas WT mice following P2 presented a further significant reduction of the colon (p= 
0.0025). Mice that were submitted to second DSS-cycle had significantly shorter colons than 
those which were allowed to rest after the first colitis induction (WT D30 P1vs P2 p= 0.0281; 
Ncf1* D30 P1 vs P2 p= 0.0229) (Fig.5 A). 
 
 Concerning the spleen's weight, at baseline Ncf1* mice presented a significant 
splenomegaly when compared to WT mice (p=0.0139). At day 22 there was a significant 
increase in spleen's weight in both groups when compared to baseline. Moreover, the Ncf1* 
mice had significantly heavier spleens than WT (p<0.0195). At day 30, regardless of protocol, 
both mice groups kept the high spleen weight as at day 22 (Fig.5 B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Fig.5  Colitis induction alters colons length and spleen weight in both animal groups. A) Colon’s length in 
centimeters, for days 0, 22 and 30. B) Spleen’s weight in grams for days 0, 22 and 30. Asterisks indicate 
p<0.05, Mann-Whitney test was performed between T0 Ncf1* and T0 WT; T1 Ncf1* and T1 WT; T2 Ncf1* 
and T2 WT  and Rec Ncf1 * and Rec WT. 
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4.2 Histopathological assessment of DSS-Induced Colitis 
 The assessment of colon histopathology score was done in untreated WT and Ncf1* 
animals, and after colitis induction at days 22 and 30 for P1 and at day 30 for P2, to evaluate 
dysplasia, epithelial morphology and inflammation, according to the described scoring criteria.  
 At baseline WT mice had well designed glands above muscuralis mucosae, whereas 
Ncf1* mice showed a reduced number of glandular tubules (Fig.6 and Table 1, Day 0). 
 On day 22 P1 WT mice maintained preserved epithelial morphology and villous 
projections plus low grade inflammatory reactive dysplasia. The Ncf1* group presented villous 
projections formed by compacted glands with less vascularization in the pedicle, plus glandular 
high grade dysplasia and invasive tubular adenocarcinoma foci (Fig.6, and Table 1, Day 22). 
 On day 30 the mice in P1 had reparative villous and glandular adaptation. WT mice 
maintained villous projections corresponding to half of the mucosae length, supported by 
tubular/glandular hyperplasia above the muscularis mucosae, with different sizes and 
segments of very small glands with low grade dysplasia foci. In Ncf1* mice colon there was a 
reduced number of glands under villous projections, although there persisted a morphology 
similar to day 22. In general Ncf1* mice showed high grade dysplasia (with anisocariosis with 
persistent nucleoli and visible mitosis) and foci of invasive tubular adenocarcinoma while WT 
colon presented basal glands’ hyperplasia with low grade and high grade segments of dysplasia 
(Fig.6, Table 1, Day 30-P1). 
 On day 30 of P2, colonic sections showed persistent adaptation (Fig 6, Table 1, Day 30-
P2): Ncf1* proximal and dystal colonic segments kept a glandular morphology with 
hypercromatic nuclei and mucosa-associated lymphoid tissue hyperplasia; and WT colon 
presented epithelial villous projections without inflammation. In distal segments, high grade 
dysplasia persisted in both groups. Additionally, Ncf1* colon developed invasive well-
differentiated adenocarcinoma in segments where few reserve micro-glands were visible 
above mucularis mucosae, invading till the muscular propria (Fig.6, Table 1, Day 30-P2). 
 In general histopathological morphology descriptions had more inflammatory foci and 
glandular/epithelial alterations in the distal halves of colonic segments, summarized as follows: 
 The distal segment of the colon presented significantly higher inflammation score and 
higher grade dysplasia for Ncf1* mice (p=0.259 for inflammation and p=0.0135 for dysplasia, 
Fig 7 A-C). For those animals following P1 there was a better evolution of inflammation and 
dysplasia at day 30 in the WT group than in the Ncf1*. 
 Proximal colon inflammation score was significantly higher in Ncf1* mice regardless of 
induction protocol than in WT (p=0.0357 after the second induction) (Fig.7 B-D). Considering 
dysplasia, after the second induction, WT colon in both protocols presented significantly higher 
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scores than Ncf1* (p=0.0463). However, Ncf1* colon presented relevant incidence of invasive 
adenocarcinoma. 
  
Fig.6 Colonic mucosa of control, P1 and P2 WT and Ncf1* mice groups. A) Day 0 of P1 and P2: glands are smaller, 
fewer and with small epithelial cells’ nuclei in Ncf1* mice colon compared to WT. B) Day 30 of P1: WT mice colon 
with basal small glands hyperplasia (X) and high grade dysplasia; Ncf1* mice colon with superficial villous 
adapt ation and invasive tubular adenocarcinoma. C) Day 22 of P2: Both WT and Ncf1* mice colon with superficial 
villous glandular hyperplasia with inflammation reactive atypia in WT mice  colon; low grade dysplasia and 
mucinous cells hyperplasia in tubular  glands of WT mice comparing with basal high grade dysplasia in Ncf1* mice. 
D) Day 30 of P2: Superficial villous mucosae and basal cell glandular persistence with high grade dysplasia in WT 
colon compared to superficial villous atrophy and invasive tubular (well differentiated) adenocarcinoma in Ncf1* 
colon. HE staining with 100x and 400x magnifications.  
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 WT Ncf1* 
Day 30 P1  Basal glands hyperplasia 
 Segments of high grade dysplasia 
 Superficial villous adaptation 
 Invasive tubular adenocarcinoma 
Day 22 P2  Villous superficial adaptation with 
reactive atypia 
 Tubular low grade dysplasia 
(mucinous cells hyperplasia) 
 Villous superficial adaptation 
without reactive atypia 
 Tubular high grade dysplasia 
Day 30 P2  Villous superficial persistent 
tubular high grade dysplasia 
 Villous superficial atrophy 
 Invasive tubular adenocarcinoma 
Table 1- Comparison of the major histopathological findings.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.7 Histological evaluation of inflammation and dysplasia at distal and proximal segments of 
the colon for Ncf1* and WT mice . Asterisks indicate p<0.05, Mann-Whitney test between Ncf1* 
and WT and Ncf1* Rec and WT Rec.  
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4.3 Effects of caffeic-acid derivatives on colon-adenocarcinoma cell lines 
 Addition of CAHA to the medium presented inhibitory effects in C2BBe1 cell line in a 
dose-dependent manner (Fig.8 A). Although with no statistical significance inhibitory activity 
was stronger after 72h incubation when compared with 24h, that was notorious with 50μM-
200μM. Similar effects were obtained when CAHA was added to WIDr cell culture, with the 
exception that 10μM did not produce inhibitory effect relatively to control (Fig.8 B). Higher 
concentrations of CAHA inhibited almost completely cell proliferation in WIDr, whereas 
C2BBe1 remains with 5% proliferation at 200μM.  
 
 
 
 
 
 
 
 
 
 
 
 
4.4 Effects of caffeic-acid derivatives on PBMCs after a 6h incubation period 
 The effects of CAHA on peripheral blood mononuclear cells are shown in Fig.9 A and B. 
The addition of CAHA to the medium increased CD4+CD25+ and CD19+ cell subpopulations in a 
dose-dependent manner, with 100μM increasing proliferation 1.84 and 1.57-fold respectively, 
relatively to the control. When added in concentrations of 50μM and 100μM had a stimulatory 
effect on T helper cells (CD4+) when compared to the control. Concentrations of 10μM-100μM 
had inhibitory effect on CD19+CD80+ and inhibited in a dose-dependent manner CD19+ 
subpopulation, with 100μM decreasing 1.17-fold compared to the control. Cytotoxic T cells 
and CD8+CD25+ cells increased only with 10μM-50μM and 10μM respectively, although 
without reaching statistical significance. 
 Addition of caffeic acid increased cell percentage of CD4+ cells with statistical 
significance between 10μM and 100μM (p=0.049), 100μM increased 1.42-fold comparatively 
to the control. CA had stimulatory effect on CD4+CD25+ cells (100μM increased 1.24-fold 
compared to the control), CD8+ cells and CD19+ cells (Fig.10 A-B). Similar results to CAHA were 
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Fig.8 Effects of caffeic-acid derivatives on human colon-adenocarcinoma cell lines after 24h and 72h  
incubation periods. A) Effects of CAHA on C2BBe1 cell line. B) Effects of CAHA on WIDr cell line. 
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seen in CD19+CD1d+, CD19+CD80+ and CD8+CD25+ cell subpopulations, where in CD8+CD25+ 
100μM increased 1.43-fold comparing to the control.   
 Results relative to PBMCs treated with FA (Fig.11 A-B) did not show any alterations in 
CD4+ and CD8+ cell subpopulations, when comparing them to the controls. However effector T 
cells percentage increased in a dose-dependent manner, but without any statistical 
significance. In CD4+/25+ 100μM increased 2.26-fold and in CD8+/CD25+ 100μM increased 2.07-
fold relatively to the control (Fig.11 A). In the case of CD19+ and CD19+CD80+ cells only 10μM 
increased cell percentage, 1.23-fold and 1.62-fold respectively, when compared to the control, 
whereas other concentrations had inhibitory effects. B regulatory cells did not suffer any 
changes relatively to the control, with the exception of 10μM that had a small inhibitory effect, 
although with no statistical significance (Fig.11 B).  
 When added to the medium FAHA only increased cell percentage of T effector 
subpopulations. In CD4+CD25+ cells, 10μM had a 22-fold increase comparing to all other 
concentrations and in CD8+CD25+ subpopulation 10μM-100μM had a 1.49, 1.35 and 1.55-fold 
increase respectively, although with no statistical significance (Fig.12 A). T helper and T 
cytotoxic subpopulations maintained equal cell percentage after the treatment relatively to 
the control, except with 10μM, that had a small inhibitory effect on cell proliferation. In B 
subpopulations, CD19+ and CD19+CD1d+ did not suffer any changes, contrary to CD19+CD80+ 
where FAHA treatment had inhibitory effect on cell proliferation, without statistical 
significance (Fig.12 B). 
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Fig.9 PBMCs incubated for 6h period with CAHA in increasing concentrations of 
0μM-100μM. A) T lymphocytes cell percentage subsets. B) B lymphocytes cell 
percentage subsets.  
Fig.10 PBMCs incubated for 6h period with CA in increasing concentrations of 
0μM-100μM. A) T lymphocytes cell percentage subsets. B) B lymphocytes cell 
percentage subsets. *p<0.05. Mann Whitney test. 
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Fig.11 PBMCs incubated for 6h period with FA in increasing concentrations of 
0μM-100μM. A) T lymphocytes cell percentage subsets. B) B lymphocytes cell 
percentage subsets. 
 
Fig.12 PBMCs incubated for 6h period with FAHA in increasing concentrations of 
0μM-100μM. A) T lymphocytes cell percentage subsets. B) B lymphocytes cell 
percentage subsets.  
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4.5 Effects of caffeic acid derivatives on PBMCs after a 12h and 24h incubation period 
 Lymphocytes are generally slow response cells, so only 6h of incubation with the 
caffeic acid derivatives may not be enough to achieve stimulatory/inhibitory results, hence we 
decided to study the long-term effects of the compounds with 12h and 24h incubation periods. 
 When cells were treated with 0-200μM of CAHA for 12h and 24h a small inhibitory 
effect was seen in T helper cells in a dose-dependent manner (with 200μM cells had a 2.2-fold 
decrease, relatively to control) (Fig.13 A). Cytotoxic T cells did not present any changes 
between concentrations and incubation periods (Fig.13 B), and the same happened to 
activated T cells (CD4+CD69+ and CD8+CD69+). However expression of CD69 in CD69+ cells 
increased in a dose-dependent manner in both CD4+CD69+ and CD8+CD69+ cell subpopulations, 
being 24h of incubation more favorable to the expression of CD69 protein, with 200μM 
increasing 5.14-fold and 4.20-fold the expression of CD69 in CD4+CD69+ and CD8+CD69+ cell 
subpopulations respectively, although with no statistical significance. Whereas the expression 
of CD25 in CD25+ cells did not show any relevant alterations, although in CD8+CD25+ CD25 
protein expression had a 1.72-fold increase relatively to the control. Effector T cells increased 
with the concentration of CAHA, CD4+CD25+ presented better results with the 24h incubation, 
with statistical significance between 200μM (p<0.05), increasing 2.95-fold. The contrary was 
seen in CD8+CD25+, with 12h incubation having significant results for 50μM, 100μM, 150μM 
and 200μM (p<0.01 to all concentrations). 
 Results from activated (CD19+CD69+) and regulatory (CD19+CD1d+) B cells presented 
statistical significance between 50μM, p<0.001 for both (Fig.13 C). Despite the results there 
was a tendency to 200μM with a 24h incubation to promote cell proliferation (CD19+  with 
200μM had a 2.80-fold increase relatively to control). Although with no statistical relevance 
200μM stimulated the expression of CD80, CD69 and CD1d+ protein, suffering a 3.61-fold, 
4.43-fold and 6.27-fold increase relatively to untreated cells. 
 Addition of FA to the medium increased cell proliferation of CD4+ and CD8+ 
subpopulations after 24h comparing to 12h incubation. T helper cells presented statistical 
significant results between 50μM-100μM p<0.01 and 150μM-200μM p<0.001, cell 
proliferation increased an average of 2.96-fold from 12h to 24h incubation (Fig.14 A), as for 
cytotoxic T cells the statistical significant results were only between 200M p<0.05 (Fig.14 B). 
Treatment with FA did not alter activated T cell subpopulations comparing with controls, 
neither the expression of CD69 in CD69+ cells, although without statistical relevance after 24h 
incubation, 50μM increased 2.53-fold and 2.39-fold the expression of CD69 protein in 
CD4+CD69+ and CD8+CD69+ respectively. Effector T cell subpopulation increased after 12h 
incubation, being 100μM-200μM more favorable to cell proliferation. 
48 
 
 FA increased an average of 8.52-fold in CD19+ subpopulation after 24h incubation 
comparing to 12h incubation, however there with no statistical significance between 
concentrations. In B lymphocytes subsets, only regulatory B cells presented statistical 
significant results between 50μM p<0.05 (Fig.14 C). Overall, concerning cell proliferation, FA 
results were better after 24h incubation period. 
 The addition of FAHA to PBMCs culture lead to a significant increase -after 24h 
incubation-  of T helper (an average of 3.01-fold increase) (Fig.14 A) and T cytotoxic cells (an 
average of 3.70-fold increase) (Fig.15 B) subpopulation for 50μM-200μM concentrations (for 
CD4+ subset, 50μM p<0.001 and 100μM-200μM p<0.01, as for CD8+ 50μM-200μM p<0.05). 
Activated T cells did not present any alterations with the treatment and as previously seen 
with FA, effector T cells proliferation increased after 12h comparing to 24h incubation 
(CD8+CD25+ 50μM p<0.05). After 24h incubation cell percentage was maintained 
independently of the FAHA concentration.  
 In the results relatively to B lymphocytes subpopulations (Fig.15 C), activated B cells 
were the only subpopulation presenting alterations (CD19+CD80+) between 200μM p<0.001. 
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Fig.13 PBMCs incubated for 12h (white bars) and 24h (black bars) periods with CAHA in in creasing 
concentrations of 0μM-200μM. A-B) T lymphocytes cell percentage subsets. C) B lymphocytes cell percentage 
subsets. Mann Whitney test and 2way ANOVA was performed between concentrations and between 12h-24h 
incubation periods, *p<0.05. 
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Fig.14 PBMCs incubated for 12h (white bars) and 24h (black bars) periods with FA in in creasing 
concentrations of 0μM-200μM. A-B) T lymphocytes cell percentage subsets. C) B lymphocytes cell 
percentage subsets. Mann Whitney test and 2way ANOVA was performed between concentrations and  
between 12h-24h incubation periods, *p<0.05. 
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Fig.15 PBMCs incubated for 12h (white bars) and 24h (bars) periods with FAHA in increasing  concentrations 
of 0μM-200μM. A-B) T lymphocytes cell percentage subsets. C) B lymphocytes cell percentage subsets. Mann 
Whitney test and 2way ANOVA was performed between concentrations and between 12h-24h incubation 
periods, *p<0.05. 
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4.6 Effects of caffeic acid derivatives on survival and proliferation of PBMCs 
 The incorporation of AV or PI allowed an assessment of the effectiveness of the 
treatments (CAHA, FA and FAHA) which could be evaluated by cell survival and proliferation 
(Fig.16).  
 Examination of cell survival in the presence of 200μM of CAHA indicated that almost 
80% of the cells remain viable after 4d of incubation and still proliferate when comparing to 
early apoptotic cells (p=0.0002), late apoptotic cells (p=0.0002) and necrotic cells (p=0.0002). 
Early apoptotic cells and late apoptotic cells percentage decreased after the treatment when 
compared to the controls, p=0.055 and p=0.0002 respectively. Necrotic cells when compared 
to early apoptotic cells and late apoptotic cells also presented relevant differences (p=0.0003, 
p=0.0002 respectively) (Fig.17 A). 
 Results of cell survival and proliferation with 150μM FA were similar to CAHA. The 
majority of the cells continued viable compared with early apoptotic, late apoptotic and 
necrotic cells (p=0.0002 to all). Early apoptotic cell percentage was higher than late apoptotic 
cells (p=0.0043) and the same to necrotic cells compared to late apoptotic cells (p=0.0002) 
(Fig.17 B). 
 Treatment with 150μM FAHA contrary to previous results inhibited cell proliferation 
comparing to the control, although not significant. Still cell survival was higher when compared 
with early apoptotic (p=0.0087), late apoptotic (p= 0.0022) and necrotic cells (p=0.002). Late 
apoptotic cells presented the lowest percentage when comparing with early apoptotic and 
necrotic cells (p=0.0022 to both) (Fig.17 C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.16 Representative dot plots of viable cells (PI
-
AV
-
), early apoptotic cells (PI
-
AV
+
), late apoptotic cells 
(PI
+
AV
+
) and necrotic cells (PI
+
AV
-
). 
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Fig.17 Clonogenic assay-effectiveness of the treatment in cell survival and proliferation. A) CAHA 
200M B) FA 150M. C) FAHA 150M. Treated cells -  black bars, controls - white bars. Mann Whitney test 
was *p<0.05. 
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5.  Discussion and conclusion 
Inflammatory Bowel Disease is a chronic relapsing idiopathic immunological disorder 
of the gastrointestinal tract, leading to long-term and sometimes permanent impairment of 
gastro-intestinal structure [1, 2]. IBD encompasses Crohn's Disease and Ulcerative Colitis. 
Evidence suggests that IBD arises from an inappropriate inflammatory immune response to 
intestinal microbes in a genetically susceptible host. Even though UC and CD have many clinical 
and pathological characteristics in common, key features separate both diseases [2-9]. Within 
the category of primary immunodeficiency  IBD depends on mutations in the NADPH oxidase 
complex, responsible for the production of ROS [9, 56, 62, 72]. In particular, a point mutation 
in the Ncf1 gene in B10.Q mice, as in humans, impairs the production of ROS, rendering them 
to increased susceptibility to bacterial infections [190], and to the development of severe 
chronic autoimmune disorders [191, 192]. The hyper inflammatory responses are directly 
associated to the inability of producing ROS, since the administration of oxidants leads to 
permanent recovery in treated animals [191, 192]. It is already known that during the acute 
phase of colitis ROS are essential to inflammation’s resolution [185], however studies focusing 
on the role of ROS-deficiency and how chronic colon-inflammation evolves to carcinogenesis 
are still missing. Furthermore, there is urgent need for effective therapies which promote 
simultaneously cancer cell death and immune system activation.  
Hence the aim was to study how the lack of ROS influenced chronic DSS-induced colitis 
and disease evolution to colon-adenocarcinoma in Ncf1-deficient mice. Moreover we 
proposed to test the therapeutic and immune-stimulatory effectiveness of caffeic acid-
derivatives in human PBMCs and human colon adenocarciona cell lines. 
 
The DSS-colitis model is commonly used in a variety of mouse strains because it is 
simple to administrate, acts rapid, its duration and severity of inflammation are controllable 
and its ability to induce disease in a great variety of mice strains [193]. Depending on the 
number of DSS-cycles or concentration, the disease can evolve from acute to chronic 
inflammation and even further to dysplasia. Furthermore, dysplasia that resembles the clinical 
course of human UC occurs frequently in the chronic phase of DSS-induced colitis [194]. 
Previous studies have shown that Ncf1* mice treated with several DSS-cycles intercalated by a 
resting period on normal water develop severer colitis, contrary to studies focused on a single 
DSS-round of colitis induction [185]. Previous studies have demonstrated that different mice 
strains are highly susceptible to colon carcinogenesis from the exposure to DSS, as IL-10-/-, 
Smad3-/- TGF-β, APC+/Min [132, 134, 136, 137, 139, 195, 196]. The administration of a 
carcinogen alongside with DSS is often preferred, since it speeds up all the process [197-199].  
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 In the present work Ncf1* mice with a single 7 days exposure to 3% DSS in drinking 
water followed by a 14 days resting period developed colonic high grade dysplasia when 
compared with low grade dysplasia found in the colon of WT mice. Furthermore after the 3 
weeks resting period, we observed lower inflammatory reparation in Ncf1* together with high 
grade dysplasia and invasive adenocarcinoma, while in WT high grade dysplasia was also 
prominent without malignant invasion. When low-grade dysplasia is detected there is a 9-fold 
risk of developing cancer, whereas high-grade dysplasia carries a 43% risk of malignancy [200, 
201]. A review by Triantafillidis et al. hypothesizes that in mechanisms concerning 
carcinogenesis, inflammation results in neoplastic transformation, by enhancing epithelial cell 
turnover in the colonic mucosa. Biopsies of areas with active inflammation from UC patients 
demonstrated higher rates of mitosis and apoptosis then seen in healthy control individuals 
[122]. Sturlan Oberhuber et al. showed that IL-10 -/- mice spontaneously develop colitis which 
leads to high grade dysplasia, which indicates that with compromised immune response the 
propensity for dysplasia increases [131, 132].  
Clinical signs of acute DSS-induced colitis were possible to be observed after the first 
DSS-cycle, however clinical signs of the chronic phase of the disease do not usually reflect the 
severity of inflammation or the histological features found in the bowel [193]. DSS toxicity to 
the colonic epithelial cells causes defects in the epithelial barrier integrity, increasing the 
colonic mucosal permeability, to allow penetration of large molecules like DSS and the entry of 
luminal antigens in the mucosa resulting in overwhelming inflammatory response. Decreased 
stool consistency and diarrhea are responsible for the marked weight loss seen in the Ncf1* 
mice. The observed shortening of the bowel was more intense in Ncf1* mice, it is caused by 
the mucosa destruction. DSS treatment shortens the colon by contracture of the smooth 
muscle tissue [202-204].  
  This results point-out this animal model as a novel tool to study chronic colitis-induced 
carcinogenesis. Several studies report either a carcinogenic path dependent on longer 
periods/multiple cycles of DSS-induction, or use carcinogenic coadjutants to reduce the 
exposure periods. Cooper HS. et al used four-cycles of DSS induction in mice to correlate 
disease-length with the development of colitis-associated dysplasia and adenocarcinoma 
[123], modelling what is thought to happen in humans. In other animal models dysplasic 
lesions take a long time to develop [123], hence disease development is not only treatment-
dependent, inherent to the strain there is a susceptibility level that may vary [205]. This 
contrasts with our model that uses just two induction cycles leading to adenocarcinoma. 
 Our study reveals some, yet unaddressed, particularities of the development of colon 
adenocarcinoma. In the histological analysis of the colon from our model, we followed the 
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2010 WHO classification of tumors of the digestive system [186] applying the human 
nomenclature for low grade dysplasia and high grade dysplasia/ intraepithelial neoplasia. As 
already clearly demonstrated stimulus-dependent inflammation is the currently recognized 
path for the development of pre-neoplastic lesions either in non-polypoid or in polypoid 
mucosa. In our model we could identify epithelial polypoid lesions/ adenomas (conventional 
tubular, villous and tubulo-villous), traditional serrated adenomas; senile serrated adenoma/ 
polyp without or with dysplasia and hamartoma-associated dysplasia. 
 Only conventional tubular, tubulo-villous and villous alterations of the flat mucosa 
superimposed to inflammation were observed without the formation of senile adenomas. 
Considering our previous observations in a model of acute DSS-colitis in the same mice [185] 
and the current chronic model, we can suggest that the inflammation process in Ncf1* colon is 
dependent of a spectrum from acute to adaptive presence of inflammatory cells. 
 ROS-influence in the studied carcinogenesis was underlined by the morphological 
alterations that were more prominent in Ncf1* mice, whereas the presence of ROS allowed 
mucosal adaptation in WT mice. As previously shown, iNOS is continuously overexpressed in 
the colon of Ncf1* mice after DSS-induction, but only transiently in WT counterparts [185]. 
Since high iNOS levels have been implicated in the progression from UC to colon 
carcinogenesis [140-145], we propose that the chronic process keeps iNOS overexpression in 
Ncf1* colon, which promotes the high grade dysplasia and adenocarcinoma formation. 
 The most relevant finding of the present study is that villous/superficial papillary 
adaptation of the flat mucosa was not relevant to adenocarcinoma morphology, while basal 
glands, the hallmark of WT response, were mostly irrelevant in Ncf1* mice, which displayed 
installed dysplasia quickly evolving to invasive well-differentiated adenocarcinoma. The WHO 
nomenclature and other studies [186, 206] recognizes several patterns for colonic tumors: 
adenocarcinoma, mucinous adenocarcinoma, signet-ring cell carcinoma and undifferentiated 
carcinoma. Our model was only capable of inducing well differentiated tubular/glandular 
adenocarcinoma, with sporadic mucous cells’ hyperplasia in foci of high grade dysplasia. These 
findings are important as they suggest that villous patterns in villous and tubulo-villous 
adenomas may not be relevant for carcinogenesis and may correspond to an epithelial 
adaptive modification, as observed in gastric peptic ulcers re-epithelization [207]. 
 Colonic adenocarcinoma is associated to hereditary genetic traits as well as 
environmental factors and ageing [208]. In ageing individual atherosclerotic mucosal atrophy 
and diet may be associated with what pathologists classify in routine biopsies as chronic 
atrophic colitis, morphologically similar to the Ncf1* mice mucosa. As anti-oxidants-rich diets 
are becoming wide-spread among the ageing population in westernized countries, our data 
58 
 
stress the indispensability of carrying out studies on how chronic diet-induced reduction of 
ROS may be implicated in colon carcinogenesis in humans. Moreover, if glandular atrophy or 
reduced number of glands above muscularis mucosae becomes demonstrated as a risk factor 
or as a pre-neoplastic condition, it will be more appropriate to introduce the concept of 
intramucosal neoplasia instead of intraepithelial neoplasia, which is currently equivalent to 
high grade dysplasia and does not correlate with adenocarcinoma aggressive invasion as it was 
demonstrated in this study. 
 
 Caffeic-acid derivatives possess anti-inflammatory, anti-oxidant and anti-tumor 
properties already reviewed in literature [158-161]. Thus, the purpose of their use in the 
present study was to evaluate if they could be considered novel anticancer agents with a dual 
role, which kills cancer cells while promoting an activation of the adaptive immune system. 
 To assess the potential anticancer activity of the caffeic-acid derivatives, CAHA was 
incubated with C2BBe1 and WIDr human colon-cancer cell lines, where the results showed a 
markedly inhibition of cell proliferation in a dose-dependent manner. Therefore, our results 
corroborate similar conclusions already obtained in previous studies. Rao Desai and its team 
studied the antimutagenic and antitumorigenic activities of several synthesized caffeic-acid 
esters, were they significantly inhibited the growth of human colon HT-29 and HCT-116 cells at 
much lower concentration, when compared to CA [167]. CA notably inhibited HCT15 colon 
cancer cell proliferation in a dose-dependent manner in a study of CA-induced apoptosis 
mechanisms [169]. 
 Our interest on these compounds was to determine whether they had low toxicity on 
human PBMCs, so we performed a clonogenic assay, hypothesizing that they would not be 
toxic to the adaptive immune system, while potentiating the activation of the immune cells. In 
a first phase assay all compounds enhanced cell proliferation of T helper, T cytotoxic and most 
importantly T effector cells (which include T regulatory cells). Based on the referred results, a 
second phase assay used concentrations were higher and longer incubation periods. CA was 
left out in this phase, due to previous results, where its effect on CD4+, CD4+/CD25+ and 
CD19+/CD1b+ cell subpopulations presented inferior cell proliferation values, when compared 
to the other caffeic-acid derivatives. Due to CA structure, higher concentrations are needed to 
achieve the same results. Similar conclusions were already described in previous studies, 
where caffeic acid ester derivatives were more lipophilic than CA and thus easily facilitate their 
entry into the cell, requiring small amounts to exhibit their effective stimulatory activities 
[163]. When incubated during 12h and 24h, PBMCs reacted better to 24h incubation period 
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and as before, caffeic-acid derivatives enhanced effector T cells proliferation. Overall PBMCs 
proliferation increased more than after 6h incubation and with higher concentrations. 
 Corresponding to our expectations the used caffeic-acid derivatives showed to have 
very low cytotoxicity towards immune cells, since about 80% remain viable with all three 
compounds, contrary to very low percentages observed in early apoptotic, late apoptotic and 
necrotic cells, while potentiating the activation of the immune adaptive cells. 
 Enhanced effector T cell proliferation induced by the caffeic acid derivative compounds 
will potentiate the immune inflammatory response, through cytokine secretion and activation 
of other immune cells, such as T helper cells (Th1 and Th2) and cytotoxic T cells. Cytotoxic T 
cells are of extreme importance, because they are responsible for the recognition and 
elimination of cells that express antigens derived from intracellular bacteria and also mutated 
or embryonic proteins, generated by cells that have undergone malignant transformation. It is 
still uncertain the extent to which T CD8+ cells are capable of controlling tumorigenesis 
development and progression, but is clear that deficiency in these cells increases the potenti al 
malignancy development [209]. Enhanced function of cytotoxic T cells allow robust antitumor 
responses in both animal models and human [210], although insufficient to fully protect from 
tumors.   
 The possible proliferative effect of the compounds on Treg cells proliferation would be 
important in tumor prevention, as they function to maintain immune homeostasis and limit 
the exacerbated immune response, they are effective in the prevention and down-regulation 
of inflammation of IBD in animal models. It is now hypothesized that Tregs might suppress 
inflammation induced by growth promoting immune system cells [211]. Although Treg cells are 
present in peripheral blood and intestine of IBD patients, active disease is characterized by 
contraction of the peripheral Treg cell pool and insufficient increase of Treg cells in the 
intestinal lesion [212]. Furthermore studies on Treg cells associated high levels of the same 
with a favorable prognosis in CRC [213].    
 Even though we shed a new light into the dual capacity of caffeic acid derivatives to 
promote both cancer cell death and activation of the adaptive immune system cells, further 
studies must be carried out, in order to assess their full capacity as novel drug candidates. 
Those studies should focus on their effects on the innate immune cells (dendritic cells, 
monocytes and NK cells). Additionally, in vitro co-cultures of caffeic-acid treated PBMCs with 
C2BBe1 and WIDr cell lines, would provide important data on whether the tumor death 
promoted by the compounds can be potentiated by the presence of activated immune cells. 
Another important issue, is to test the preventive action of these compounds in active IBD 
patients, mainly through their capacity to promote the expansion of the Treg pool. This could 
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be initially studied using the Ncf1*-model by administering these compounds in physiologically 
active doses prior to DSS-colitis induction. 
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